慢病毒载体使用手册
慢病毒使用手册
慢病毒使用手册慢病毒(Lentivirus)是一类非常常见的病毒,它属于逆转录病毒家族。
与其他病毒相比,慢病毒具有一些特殊的特征,使其在生物研究领域和基因治疗等应用中变得非常重要。
本文将介绍慢病毒的基本特征、制备和使用方法,以及慢病毒在基因转染、基因表达和基因治疗中的应用。
一、慢病毒的基本特征慢病毒是一类具有外包膜的病毒,其基因组由一条单链正义RNA组成。
慢病毒具有较大的基因载量能力,可携带长达9kb的外源DNA序列。
另外,慢病毒具有高度的细胞性选择性,能够感染多种哺乳动物细胞,并将外源基因稳定地集成到细胞基因组中。
二、慢病毒的制备方法慢病毒的制备包括构建慢病毒载体和包装慢病毒。
构建慢病毒载体通常采用三元质粒系统,其中包括基因载体、包装载体和包衣载体。
基因载体负责携带外源基因序列,而包装载体负责表达与慢病毒复制有关的基因,如gag、pol和env等。
包衣载体则负责表达包衣蛋白,使慢病毒能够正常装配和释放。
包装慢病毒的方法通常采用转染细胞的方式。
将构建好的慢病毒载体与包装载体和包衣载体一同转染到特定的细胞中,通过包装载体表达的基因来启动慢病毒的复制和包装过程。
经过适当的培养和处理后,可以获得高效包装的慢病毒颗粒。
三、慢病毒的使用方法慢病毒主要通过基因转染、基因表达和基因治疗等方式应用于生物研究和医学领域。
1. 基因转染:慢病毒可以用于将外源基因导入到细胞中,实现基因转染。
通过选择性的感染特定细胞或细胞系,可以研究和探索特定基因的功能和调控机制。
2. 基因表达:慢病毒可以被用作基因表达工具。
外源基因在细胞内被稳定地整合到基因组中,从而实现长期稳定的基因表达。
慢病毒可以用于产生稳定的细胞株,并通过基因敲入或敲除等方法研究基因功能。
3. 基因治疗:慢病毒在基因治疗中的应用非常广泛。
通过将修正后的基因导入到患者体内的细胞中,可以实现对某些慢病毒引起的遗传疾病的基因治疗。
此外,慢病毒载体还可以用于制备疫苗和用于癌症免疫治疗等领域。
慢病毒使用操作指南
慢使用操作指南操作指南:慢使用1、简介1.1 背景介绍1.2 慢的定义1.3 慢的应用领域2、仪器与材料2.1 实验室安全设备2.2 实验室试剂和材料2.3 慢载体和质粒3、慢的生产3.1 慢生产细胞系的选择3.2 质粒构建与筛选3.3 慢包装细胞的构建与筛选3.4 慢的生产与扩增4、慢的感染4.1 细胞培养与准备4.2 慢感染的条件优化4.3 慢感染的时间和浓度控制5、慢的转染5.1 细胞转染前的处理5.2 转染的操作条件5.3 考虑的转染效率和细胞毒性问题6、实验细胞系的维护6.1 细胞的培养和传代6.2 细胞的冻存与恢复6.3 实验细胞系的检测和验证7、实验数据记录与分析7.1 实验数据的记录和整理7.2 数据分析方法与软件使用7.3 结果的展示和解释8、安全注意事项8.1 实验操作安全措施8.2 废液处理及废弃物管理8.3 慢实验室传播的预防措施9、附件9.1 相关实验记录表格9.2 质粒和慢载体序列信息法律名词及注释:1、载体:在基因工程中,指用来携带或传递目标基因的DNA或RNA分子。
2、质粒:指自主复制的独立DNA分子,可被插入或移除目标基因,用于基因克隆、表达和操控等实验。
3、细胞培养:通过体外培养细胞的技术,提供实验所需的可控环境和条件。
4、转染:将外源DNA或RNA导入细胞内,使其表达或转录的过程。
5、传代:将细胞从一个培养器转移到另一个培养器,以维持细胞系的生长。
6、冻存:将细胞以特定的方法冷冻保存,以备将来使用。
7、废液处理:对实验过程中产生的含有有害或感染性物质的废液进行妥善处理,避免对环境和人体造成危害。
8、废弃物管理:对实验中产生的废弃物进行分类、包装和处理,符合相关法规和标准。
本文档涉及附件:1、慢生产记录表2、慢感染实验记录表3、细胞培养和传代记录表4、实验数据分析表格本文所涉及的法律名词及注释:载体、质粒、细胞培养、转染、传代、冻存、废液处理、废弃物管理。
pPACKH1-REV慢病毒载体使用说明
pPACKH1-REV慢病毒载体使⽤说明pPACKH1-REVpPACKH1-REV 载体基本信息:载体名称:pPACKH1-REV 质粒类型: 慢病毒包装载体⾼拷贝/低拷贝: ⾼拷贝克隆⽅法: 限制性内切酶,多克隆位点启动⼦:CMV 载体⼤⼩:5.5kb 5' 测序引物及序列: CMV Forward : CGCAAATGGGCGGTAGGCGTG3' 测序引物及序列:-- 载体标签:-- 载体抗性: 氨苄青霉素筛选标记:-- 克隆菌株: TOP10等常规菌株宿主细胞(系): 哺乳动物细胞系备注:第三代慢毒包装载体pPACKH1-GAG 与pPACKH1-REV, pVSV-G 是基于HIV-1的慢病毒包装系统。
⽤于第三代慢病毒载体的包装,如: pCDH-CMV-MCS-EF1-puro pCDH-CMV-MCS-EF1-copGFP pCDH-CMV-MCS-EF1-copGFP-T2A-puro pCDH-CMV-MCS-EF1-RFP pCDH-MCS-T2A-puro-MSCV 稳定性: 瞬表达组成型/诱导型: 组成型病毒/⾮病毒: ⾮病毒pPACKH1-REV 载体质粒图谱和多克隆位点信息:pPACKH1-REV载体简介:慢病毒包装质粒pPACKH1-REV使⽤⽅法——慢病毒包装与转染⽅法Production of lentiviral viral stocks requires HIV-1 gag, pol, and rev gene products and vesicular stomatitis virus G (VSV-G) protein encoded by helper plasmids. In general, at least two helper plasmids are required, with one plasmid expressing the Gag-Pol polyprotein and an accessory protein Rev and the other expressing VSV-G as envelop protein to increase cell tropism. Nevertheless, Gag-Pol and Rev proteins can be expressed from separated plasmids as well. Therefore, a three-plasmid system or a four-plasmid system can be used to generate viral stocks, depending on the source and nature of the helper plasmids. In the three-plasmid system, lentiviral transfer vector is cotransfected with two helper plasmids (Gag-Pol + Rev and VSV-G) into cells, while in the four-plasmid system; lentiviral transfer vector is cotransfected with three helper plasmids (Gag-Pol, Rev and VSV-G). It is generally considered to be safer to produce the lentiviral stocks with more helper plasmids, due to the reduced chance of recombination among all vectors that generates replication-competent viruses. The manufacturers of transfection reagents, the suppliers of lentiviral packaging constructs, and many academic laboratories have provided protocols for producing lentiviral stocks. The following procedure is provided as an example only. We produce lentiviral stocks in 293T cells using theBelow we have listed the commonly used vectors for lentiviral packaging.1 For example: pCMV-deltaR8.91 (TRC), psPAX2 (Addgene)2 For example: pMDLg/pRRE (Addgene), pLP1 (Invitrogen), pPACKH1-GAG (SBI)3 For example: pRSV-REV (Addgene), pLP2 (Invitrogen), pPACKH1-REV (SBI)4 For example: pMD.G (TRC), pMD2.G (Addgene), pCMV-VSV-G (Addgene), pVSV-G (SBI), pLP/VSVG (Invitrogen) Note: The transfection reagent Lipofectamine? 2000 (LF2000, Invitrogen) is preferred for transfection. The average lentiviral titers in our preparations are around5 x 106 - 5 x 107 infection units per ml(IU/ml) when titered with 293T cells.Day 0: Seed 6.0 × 106 (1.0 × 106) 293T cells in a 10-cm plate (6-well plate), so that the cell density willbe around 1.0 × 107 (1.7 × 106) at the time of transduction.Day 1: Gently mix 45.0 (7.5) µl LF2000 and 1.5 (0.25) ml Opti-MEM medium and incubate at room temperature for 5 minutes. Meanwhile, gently mix 18.0 (3.0) µg in total of lentiviral transfer vector and helper plasmids mixture into 1.5 (0.25) ml Opti-MEM medium (Invitrogen).Gently mix DNA and LF2000, incubate at room temperature for 20 minutes to allow DNA and lipid to form complexes. In the meantime, replace the overnight culture medium with 5.0 (1.0) ml DMEM + 10% FBS without antibiotics. Add the 3.0 (0.5) ml DNA-LF2000 complexes to 293T cells.Note: We have noticed that fetal bovine serum purchased from different manufacturers may affect the attachment of 293T cells to the bottom of tissue culture plates, resulting in variation in the efficiencyof lentiviral production. We recommend switching to a different brand of FBS if 293T cells disattach from plates during lentiviral production.Day 2: Replace the media containing the DNA-LF2000 complexes with 10.0 (2.0) ml complete medium at 12-16 hours post-transfection.Day4: Collect supernatants at 48 hours post-transfection and transfer media to a polypropylene storage tube. Spin the virus-containing media at 1300 rpm for 5 minutes to pellet any 293T cells that were carried over during collection. Carefully transfer the supernatant to a sterile polypropylene storage tube.Note: Lentiviral stock may be stored at 4 °C for up to 5 days, but should be aliquoted and frozen at-80 °C for long-term storage.Suggestion: To reduce the number of freeze and thaw cycles, aliquot lentiviral stock to smaller tubes before storage at -80 °C. Titering the lentiviral stocksIt is important to titer the lentiviral stocks in the cell line of interest to produce consistent results usingthe equivalent multiplicity of infection (MOI) in experiments. Knowing MOI will help you to control the copy number of lenti-cDNA integrated into the chromosomes of the cells of interest. While titering virus with antibiotic selection, the titering procedure includes selection of stably transduced cells with the corresponding antibiotics and counting the antibiotic-resistant cell colonies. Alternatively, a flow cytometry can be used to determine the viral titer by measuring the number of green (or red) fluorescent cells. If you are using both methods to titer your lentiviruses, please keep in mind that the titers may be different due to sensitivities of FACS machine and cell lines resistant to drug selection. Please be aware the lenti-cDNA virus titer may be underestimated when antibiotic selection or flow cytometry is deployed to determine the titer. For example, the transduced cells with single integration event may not be selected due to low level of selection marker expression by IRES.A. Determination of lentiviral titers by antibiotics selection.Day 0: Seed the cells of your choice in a 6-well plate so that the cell density that will be ~25-50% confluent at the time of transduction.Day 1: Thaw lentiviral stock, gently mix virus and then prepare 2 ml 10-fold serial dilutions ranging from 10-3 to 10-7 in complete medium containing 5-8 µg/ml polybrene.Remove the medium from previous day and add 2 ml fresh dilutions into each well.Suggestion: Leave one well uninfected for mock control. Spin transduction in a desktop centrifuge (e.g. Sorvall RT6000) at 1,000 × g for 30-60 min at room temperature may be necessary if titering virus in cell lines other than 293T.Day 2: Replace the medium containing virus and polybrene with 2 ml of complete medium.Day 3-4: Replace medium with fresh medium containing antibiotic to select for stably transduced cells. Note: At least 48 hours of transduction allows lenti-cDNA to integrate into the host genome. The optimal antibiotic concentration varies from cell line to cell line.Suggestion: A pilot experiment should be performed to determine the minimum concentration of antibiotics required to kill the untransduced cells before this experiment.Day 5-6: Replace medium with 2 ml fresh medium containing antibiotic every 2 days.Day 7-8: Allow antibiotic-resistant colonies to form in dilution wells. No live cells should be growing in the mock control well. Note: The number of days required for the formation of visible colonies may vary among different cell lines.Wash wells twice with 2 ml PBSStain cells with 1 ml 0.5% crystal violet solution in 20% ethanol and incubate for 30 minutes at room temperature.Wash wells with distilled water by submerging the plate in a tray full of water, and repeat the wash one more time.Dry the plate and count the number of blue-stained colonies.The titer should be the average colony number times the dilution factor.Note: The transduction efficiency varies from cell line to cell line. The lentiviral titer in the cell line of your interest may be lower (sometimes more than 10-fold) or higher than the virus titer in commonly used cell lines such as 293T cells.B. Determination of lentiviral titers by flow cytometry.Day 0: Seed the cell of your choice in a 6-well plate so that the cell density that will be ~25-50% confluent at the time of transduction.Note: The number of cells seeded in the well is required to calculate lentiviral titer later.Day 1: Thaw lentiviral stock, gently mix virus and then prepare 2 ml 10-fold serial dilutions ranging from 10-1 to 10-4 in complete medium containing 5-8 µg/ml polybrene.Remove the medium from previous day and add 2 ml fresh dilutions into each well.Suggestion: Leave one well uninfected for mock control. Spin transduction in a desktop centrifuge (e.g. Sorvall RT6000) at 1,000 × g for 30-60 min at room temperature may be necessary if titering virus in cell lines other than 293T.Day 2: Replace the medium containing virus and polybrene with 2 ml of complete medium.Day 3-4: Follow your lab protocol to collect and resuspend cells for flow cytometry to determine the percentage of green or red fluorescent cells.Note: At least 48 hours of transduction allows lenti-cDNA to integrate into the host genome.The titer should be the average number of live fluorescent cells times the dilution factor.Note: The transduction efficiency varies from cell line to cell line. The lentiviral titer in the cell line of your interest may be lower (sometimes more than 10-fold) or higher than the virus titer in commonly used cell lines such as 293T cells. Example: 1 × 105 cells were seeded on Day 0 and the cell doubling time is around 24 hours. The FACS data showed 5% and 40% of green fluorescence cells in the 10-3 and 10-2 dilution wells, respectively. The lentiviral titer is calculated by multiplying the fraction of transduced cells by 2 × 105 (the expected number of cells in the well on Day 1, the time of transduction), and by the dilution factor.0.05 × (2 × 105) × 103 = 1 × 1070.4 × (2 × 105) × 102 = 8 × 106The average lentiviral titer is 9 × 106 IU/mlLentiviral Transduction for Gene Expression.Day 0: Seed cells at appropriate density.Suggestion: Plate cells so that cell density will be ~10-25% confluent at the time of transduction.Day 1: Transduction. Remove the medium from the tissue culture plate by aspiration and replace itwith fresh complete medium containing 5-8 µg/ml polybrene. Gently mix lentivirus with pipette tip,and add appropriate amount of virus to each well.Note: (1) Polybrene may be toxic to some cell lines. (2) The non-concentrated and non-purifiedlentiviral stock collected from 293T supernatant may contain substances affecting the target cell growth, especially when a large volume of low-titer lentiviral stock is added. In case the lentiviral stock inhibits cell growth, concentration and purification of the viruses may be required. (See below for a protocol of virus concentration) Alternatively, incubation time for transduction can be shortened to hours. For example, the virus-containing medium may be replaced with fresh medium after one hourof transduction.Suggestion: Transduce cells at multiplicity of infection (MOI) = 1, 5, 10, 25, and 50 to determine the optimal expression level. Spin transduction in a desktop centrifuge (e.g. Sorvall RT6000) at 1,000 × gfor 30-60 min at room temperature helps increase of transduction efficiency.Day 2: Replace the transduction medium with fresh complete medium to remove lentivirus and polybrene.Day 3-4: Select transduced cells (>50% confluence is recommended) with medium containing appropriate antibiotics or by flow cytometry to sort out fluorescence-positive cells if necessary.Note: The optimal antibiotic concentration varies from cell line to cell line.Suggestion: A pilot experiment should be performed to determine the minimum concentration of antibiotic required to kill the untransduced cells before this experiment.Day 6+: Analysis of transduced cells.Suggestion: Expand the culture of cell lines stably expressing GOI and store the cell line stocks in liquid nitrogen before analyzing the cells.Optional: Concentration of lentivirus by ultracentrifugation1. Filter lentivirus through a 0.45 µm filter.2. Centrifuge at 25,000 rpm for 90 minutes in a SW-28 or SW-41 rotor.3. Discard the supernatant and use a Pasteur pipette with an attached P100 tip to carefully removethe remaining medium.4. Gently resuspend viral pellet in 1/100 volume of DMEM. Let the virus suspension sit for overnightat 4° C.5. On the following day, mix gently, aliquot and freeze virus.pPACKH1-REV载体序列pPACKH1-REV其他相关慢病毒载体:Tet-pLKO-neo Tet-pLKO-puro pPACKH1-GAG pMD2.G pCMV-dR8.2-dvpr pLKO.1-GFP-shRNA pLKO.1-TRC control pLKO.1-hygro pLKO.1-TRC pCDH-MSCV-MCS-EF1-copGFP pCDH-MSCV-MCS-EF1-copGFP-T2A-Puro FUW-tetO-hOKMSFUW-tetO-hOCT4 FUW-tetO-hSOX2 FUW-tetO-hKLF4FUW pLVX-AcGFP1-N1 pLVX-AcGFP1-C1pLVX-AmCyan1-N1 pLVX-DsRed-Express2-C1 pLVX-DsRed-Express2-N1 pLVX-DsRed-Monomer-N1 pLVX-PAmCherry-C1 pLVX-PAmCherry-N1pLVX-ZsGreen1-N1 pLVX-IRES-ZsGreen1 pLVX-IRES-mCherrypLVX-mCherry-C1 pLVX-mCherry-N1 pLVX-tdTomato-C1pLKO.1-puro pLentilox 3.7 pLVX-Tet-On-Advanced pLVX-IRES-Puro pLVX-IRES-Neo pLVX-IRES-HygpLVX-EF1α-DsRed-Monomer-C1 pLVX-EF1α-AcGFP1-N1 pLVX-EF1α-AcGFP1-C1 pLVX-EF1α-mCherry-C1 pLVX-EF1α-IRES-mCherry pLVX-EF1α-IRES-ZsGreen1 pLVX-MetLuc Control pLVX-MetLuc pLVX-Hom-Mem1pLVX-Het-2 pLVX-DD-AcGFP1-Actin pPRIME-TET-GFP-FF3pSIH1-H1-CopGFP pCDH-EF1-MCS-T2A-Puro pCDH-CMV-MCS-EF1-Puro pCDF1-MCS2-EF1-copGFP pLOX-CWBmi1 pLOX-CW-CREpRSV-rev pMDLg-pRRE pLL3.7pLVX-DD-AmCyan1 Control pLVX-DD-AmCyan1 Reporter pLVX-DD-tdTomato Reporter pLVX-DD-tdTomato Control pLVX-PTuner-Green pLVX-CherryPicker2pLVX-TetOne-Puro-Luc pLVX-TetOne pLVX-TetOne-PuropLVX-TetOne-Luc pLVX-rHom-Nuc1 pLVX-rHom-Sec1pLVX-rHom-1 pLVX-Hom-Nuc1 pLVX-Het-Nuc1pLVX-PTuner pLVX-PTuner2 pLVX-DD-ZsGreen1 Reporter pLVX-Het-1 pLVX-CherryPicker Control pLVX-Tet3GpCDH-CMV-MCS-EF1-RFP-T2A-Puro pCDH-CMV-MCS-EF1-Hygro pCDH-CMV-MCS-EF1-Neo pCDH-MCS-T2A-Puro-MSCV pCDH1-MCS2-EF1-copGFP pCDF1-MCS2-EF1-Puro pCDH-EF1-MCS-T2A-copGFP pWPXL pLVX-TRE3G-ZsGreen1 pLVX-TRE3G-mCherry pLenti6.3-EmGFP-BveI miR pLenti6/V5-GW/lacZpLenti6.3/V5-GW/EmGFP pLenti6.3-MCS pLenti6.3-DsRed2-BveI miR pLenti6.3-MCS-IRES2-EGFP pLVX-shRNA2 psPAX2 VSV-G pSico PGK Puro pcDNA6.2-DsRed2-MCS1 miR pcDNA6.3-EmGFP-NC- II pcDNA6.2-EmGFP-NC- I pcDNA6.2-EmGFP-BsaI miR pLenti6.3-BveI miR pLenti6.3-MCS-IRES2-DsRed2 pLEX-MCSpGIPZ pLP2 pLP1FUGW pFUGW pLOX-Ttag-iresTKpMDLg/pRRE pLentG-KOSM pCMV-dR8.91pLVX-TRE3G-Luc Control pLVX-TRE3G-IRES pCgpvpSico pSicoR pLVTHMpGensil-1 pLVX-EF1α-IRES-Puro pCDF1-MCS2-EF1-copGFP pPACKH1-REV pLVX-Het-Mem1 pLVX-shRNA1pLKO.1-puro-GFP-siRNA pPRIME-TREX-GFP-FF3 pcDNA6.2-DsRed2-BsmBI miR pCDH-MSCV-MCS-EF1-Puro pCDH-CMV-MCS-EF1-copGFP pLVX-TRE3GFUW-tetO-hMYC pLOX-TERT-iresTK pLP/VSVGFUW-M2rtTA pCDH-EF1-MCS-(PGK-Puro) pcDNA6.2-EmGFP-MCS1 miR pLVX-AmCyan1-C1 pLVX-Hom-1 pcDNA6.2-BsaI miRpLVX-DsRed-Monomer-C1 pLVX-mCherry-Actin pTRIPZpLVX-ZsGreen1-C1 pLVX-CherryPicker1 LeGO-iC2 pLVX-IRES-tdTomato pCDH-CMV-MCS-EF1-copGFP-T2A-Puro pLKO.3GpLVX-tdTomato-N1 pLVX-PTuner2-C pLVX-Puro pLVX-Tight-Puro pLVX-DD-ZsGreen1 Control pSicoR PGK Puro pLVX-EF1α-DsRed-Monomer-N1 pCDH-UbC-MCS-EF1-Hygro pLVTHpLVX-EF1α-mCherry-N1 pCDH-CMV-MCS-EF1-RFP。
慢病毒使用手册
培养基(DMEM+10% FBS,高糖); C. 取待测定的病毒原液 11 µl 加入到第一个管中,混匀后,取 11 µl 加入到第
二个管中。继续相同的操作直到最后一管;
Shanghai GeneChem Co.,Ltd
Floor 2, NO.328,Aidisheng Rd . Pudong,Shanghai,201203 P.R.C. TE:(86)21 51320189 FAX:(86)21 51370635
-Page 6 of 17-
Lentiviral Vector Particle 使用操作手册
Lentiviral Vector Particle 使用操作手册
上海吉凯基因化学技术有限公司
二○一一年七月
Partner in gene function and drug target validation
Lentiviral Vector Particle 使用操作手册
手册内容
一.Lentivirus 的储存与稀释 二.Lentivirus 使用安全注意事项 三.Lentivirus 在体外培养原代细胞和细胞系水平的使用 四.常见问题 五.细胞 MOI 值列表
义为感染时病毒和细胞数量的比值。在我们实验中将某个细胞达到 80%感 染时所需的 MOI 值定义为这个细胞的 MOI 值。 Polybrene:是常用的感染添加剂,使用浓度为 5-10 µg/ml,polybrene 能显著
提高病毒对细胞的接触并提高病毒的感染效率,在一般细胞上有 3-4 倍的作用,对有些细胞可以提高 10-20 倍;吉凯基因提供的 Polybrene 储液浓度为 10 mg/ml,如有需要,使用过程中也可以 用 D-hanks,PBS 或培养基进行稀释。 ENi.S.:Enhanced Infection Solution(ENi.S.)是吉凯开发的感染增强溶液,使用 时需将培养基弃去,替换为 ENi.S.,然后加入病毒,也可以同时加入 polybrene。ENi.S.亦可以显著提高病毒对细胞的感染能力。
汉恒生物-慢病毒生产及使用操作手册第二版
2. 感染细胞最佳 MOI 的测定 MOI(Multiplicity of Infection,感染复数)是指每个细胞感染的病毒
数,通常 MOI 越高,病毒整合到染色体的数量以及目的蛋白的表达量越高。 对于分裂活跃的细胞,比如 Hela、293 细胞,MOI=1~3 时,80%以上的细胞均表 达目的基因。而对于非分裂细胞,比如原代细胞,感染效率较低。需要进行 MOI 梯度摸索实验,选择适合的 MOI 进行实验。
四、慢病毒包装和浓缩 (一)质粒扩增
构建好的慢病毒载体和辅助质粒需经过大量抽提,浓度大于 1ug/ul,A260/280 在 1.7-1.8 间方可用以包毒。推荐使用 Qiagen 大抽试剂盒进 行质粒的大量去内毒素抽提。 (二)传 293T 细胞
将培养 293T 细胞 T75 瓶中的培养基吸净,加入 2mL 4 度冰箱取出的 0.25% 胰酶,使其均匀覆盖瓶底,置于 37 度培养箱中 3-5min,取出,摇晃可发现细胞 于底部脱离,将其全部晃下,加入 3mL 37 度水浴中预热的 10% DMEM,移液枪 用 10mL 移液管进行吹打,较大力吹打 6-8 次即可,不留死角,瓶口处较难吹打 可将移液管对准培口,小力将培养基打出即可覆盖到接近瓶口的细胞。之后,将 所有细胞吸出,置于 15mL 离心管中,取 50ul 混匀后的细胞于 1.5mL eppendorf
当细胞传代次数过多,细胞状态变差时,或者细胞出现污染事故时,需要丢 弃并对最初冻存的细胞进行复苏。
1、设置温度为 37~42℃的水浴。 2、查看细胞库记录,根据记录从液氮罐中取出冻存的细胞(需戴上棉手套, 防止被冻伤),迅速丢入水浴锅中并快速晃动,尽量在 1~2min 内使细胞溶液完全 溶解。 3、将细胞溶液转移到 15ml 离心管中,并在其中加上 1ml 新鲜的完全培养 基,混匀后离心,1000rpm,5min。 4、去掉上清,加入 5ml 新鲜的完全培养基,混匀沉淀后,转入 6cm 培养皿。 5、将培养皿平稳放入 37℃、5%CO2 和 95%相对湿度的培养箱中培养。 6、第二天观察细胞存活率。给细胞换一下培养基。以后每天观察细胞生长 情况。
慢病毒载体构建及包装操作手册
慢病毒载体构建及包装操作手册目录慢病毒收到后的注意事项一、整体实验流程二、实验材料三、慢病毒包装和浓缩四、感染目的细胞附1. 汉恒生物慢病毒质粒列表附2. 慢病毒滴度测定方法简介附3. 慢病毒MOI感染参数附4. 汉恒生物各病毒载体感染目的细胞比较慢病毒安全使用和注意事项➢慢病毒安全使用注意事项(*非常重要!!!*)1)慢病毒相关实验请在生物安全柜(BL-2级别)内操作。
2)操作病毒时请穿实验服,佩戴口罩和手套,尽量不要裸露双手及手臂的皮肤。
3)操作病毒时特别小心病毒溅出。
如果操作时超净工作台有病毒污染,请立即用70%乙醇加1%的SDS溶液擦拭干净。
接触过病毒的枪头,离心管,培养板,培养液请于84消毒液浸泡后统一处理。
4)如需要离心,应使用密封性好的离心管,如有必要请用封口膜封口后离心。
5)病毒相关的废弃物需要特殊收集,统一经高温灭菌处理。
6)实验完毕用香皂清洗双手。
➢慢病毒收到后的注意事项1)慢病毒的储存用户收到病毒液后在短期内即使用慢病毒进行实验,可以将病毒暂时放置于4 ℃保存(尽量一周内用完);如需长期保存请分装后放置于-80℃。
注:a.反复冻融会降低病毒滴度(每次冻融会降低病毒滴度10%-50%);在病毒使用过程中应尽量避免反复冻融,所以我们前期对病毒进行了分装(200 l/tube),收到后直接放置-80℃保存即可。
b.如果病毒储存时间超过6个月,我们建议在使用前重新测定病毒滴度。
2)慢病毒的稀释用户需要稀释病毒时,请将病毒取出置于冰浴融解后,使用培养目的细胞用PBS或无血清培养基(含血清或含双抗不影响病毒感染)混匀分装后置于4℃保存(请尽量一周内用完)。
一、整体实验流程二、实验材料(一)慢病毒载体、包装细胞和菌株该病毒包装系统为三质粒系统,组成为psPAX2, pMD2.G, pHBLV TM系列质粒。
1、载体信息(见附表1)2、细胞株:我们采用293T作为慢病毒的包装细胞。
该细胞系为贴壁依赖型成上皮样细胞,生长培养基为DMEM+10% FBS+双抗。
VSV-G慢病毒载体使用说明
VSV-GVSV-G载体基本信息:载体名称: VSV-G质粒类型: 慢病毒包装系统载体高拷贝/低拷贝: --启动子: --克隆方法: 多克隆位点,限制性内切酶载体大小: --5' 测序引物及序列: --3' 测序引物及序列: --载体标签: --载体抗性: --筛选标记: --备注: --稳定性: --组成型: --病毒/非病毒: --VSV-G载体质粒图谱和多克隆位点信息VSV-G载体序列VSV-G其他相关慢病毒载体:Tet-pLKO-neo Tet-pLKO-puro pPACKH1-GAGpMD2.G pCMV-dR8.2-dvpr pLKO.1-GFP-shRNA pLKO.1-TRC control pLKO.1-hygro pLKO.1-TRCpCDH-MSCV-MCS-EF1-copGFP pCDH-MSCV-MCS-EF1-copGFP-T2A-Puro FUW-tetO-hOKMSFUW-tetO-hOCT4 FUW-tetO-hSOX2 FUW-tetO-hKLF4FUW pLVX-AcGFP1-N1 pLVX-AcGFP1-C1pLVX-AmCyan1-N1 pLVX-DsRed-Express2-C1 pLVX-DsRed-Express2-N1 pLVX-DsRed-Monomer-N1 pLVX-PAmCherry-C1 pLVX-PAmCherry-N1 pLVX-ZsGreen1-N1 pLVX-IRES-ZsGreen1 pLVX-IRES-mCherry pLVX-mCherry-C1 pLVX-mCherry-N1 pLVX-tdTomato-C1 pLKO.1-puro pLentilox 3.7 pLVX-Tet-On-Advanced pLVX-IRES-Puro pLVX-IRES-Neo pLVX-IRES-HygpLVX-EF1α-DsRed-Monomer-C1 pLVX-EF1α-AcGFP1-N1 pLVX-EF1α-AcGFP1-C1 pLVX-EF1α-mCherry-C1 pLVX-EF1α-IRES-mCherry pLVX-EF1α-IRES-ZsGreen1 pLVX-MetLuc Control pLVX-MetLuc pLVX-Hom-Mem1pLVX-Het-2 pLVX-DD-AcGFP1-Actin pPRIME-TET-GFP-FF3pSIH1-H1-CopGFP pCDH-EF1-MCS-T2A-Puro pCDH-CMV-MCS-EF1-Puro pCDF1-MCS2-EF1-copGFP pLOX-CWBmi1 pLOX-CW-CREpRSV-rev pMDLg-pRRE pLL3.7pLVX-DD-AmCyan1 Control pLVX-DD-AmCyan1 Reporter pLVX-DD-tdTomato Reporter pLVX-DD-tdTomato Control pLVX-PTuner-Green pLVX-CherryPicker2pLVX-TetOne-Puro-Luc pLVX-TetOne pLVX-TetOne-PuropLVX-TetOne-Luc pLVX-rHom-Nuc1 pLVX-rHom-Sec1pLVX-rHom-1 pLVX-Hom-Nuc1 pLVX-Het-Nuc1pLVX-PTuner pLVX-PTuner2 pLVX-DD-ZsGreen1 Reporter pLVX-Het-1 pLVX-CherryPicker Control pLVX-Tet3GpCDH-CMV-MCS-EF1-RFP-T2A-Puro pCDH-CMV-MCS-EF1-Hygro pCDH-CMV-MCS-EF1-Neo pCDH-MCS-T2A-Puro-MSCV pCDH1-MCS2-EF1-copGFP pCDF1-MCS2-EF1-Puro pCDH-EF1-MCS-T2A-copGFP pWPXL pLVX-TRE3G-ZsGreen1 pLVX-TRE3G-mCherry pLenti6.3-EmGFP-BveI miR pLenti6/V5-GW/lacZpLenti6.3/V5-GW/EmGFP pLenti6.3-MCS pLenti6.3-DsRed2-BveI miR pLenti6.3-MCS-IRES2-EGFP pLVX-shRNA2 psPAX2VSV-G pSico PGK Puro pcDNA6.2-DsRed2-MCS1 miR pcDNA6.3-EmGFP-NC- II pcDNA6.2-EmGFP-NC- I pcDNA6.2-EmGFP-BsaI miR pLenti6.3-BveI miR pLenti6.3-MCS-IRES2-DsRed2 pLEX-MCSpGIPZ pLP2 pLP1FUGW pFUGW pLOX-Ttag-iresTKpMDLg/pRRE pLentG-KOSM pCMV-dR8.91pLVX-TRE3G-Luc Control pLVX-TRE3G-IRES pCgpvpSico pSicoR pLVTHMpGensil-1 pLVX-EF1α-IRES-Puro pCDF1-MCS2-EF1-copGFP pPACKH1-REV pLVX-Het-Mem1 pLVX-shRNA1pLKO.1-puro-GFP-siRNA pPRIME-TREX-GFP-FF3 pcDNA6.2-DsRed2-BsmBI miR pCDH-MSCV-MCS-EF1-Puro pCDH-CMV-MCS-EF1-copGFP pLVX-TRE3GFUW-tetO-hMYC pLOX-TERT-iresTK pLP/VSVGFUW-M2rtTA pCDH-EF1-MCS-(PGK-Puro) pcDNA6.2-EmGFP-MCS1 miR pLVX-AmCyan1-C1 pLVX-Hom-1 pcDNA6.2-BsaI miRpLVX-DsRed-Monomer-C1 pLVX-mCherry-Actin pTRIPZpLVX-ZsGreen1-C1 pLVX-CherryPicker1 LeGO-iC2pLVX-IRES-tdTomato pCDH-CMV-MCS-EF1-copGFP-T2A-Puro pLKO.3GpLVX-tdTomato-N1 pLVX-PTuner2-C pLVX-PuropLVX-Tight-Puro pLVX-DD-ZsGreen1 Control pSicoR PGK PuropLVX-EF1α-DsRed-Monomer-N1 pCDH-UbC-MCS-EF1-Hygro pLVTHpLVX-EF1α-mCherry-N1 pCDH-CMV-MCS-EF1-RFP。
pLVX-IRES-Neo慢病毒载体使用说明
pLVX-IRES-Neo pLVX-IRES-Neo载体基本信息:载体名称:pLVX-IRES-Neo, pLVX IRES Neo质粒类型: 慢病毒载体;哺乳动物细胞表达载体;双顺反子载体高拷贝/低拷贝: 高拷贝启动子: CMV克隆方法: 多克隆位点,限制性内切酶载体大小: 8269 bp5' 测序引物及序列: CMV-F: CGCAAATGGGCGGTAGGCGTG (Invitrogen)3' 测序引物及序列: IRES-R: CCTCACATTGCCAAAAGACG载体标签: 无标签载体抗性: 氨苄青霉素筛选标记: 新霉素Neomycin克隆菌株: Stbl3 E.coli备注: pLVX-IRES-Neo载体以双顺反子的形式同时表达Neo抗性基因和目的基因;CMV启动子驱动目的基因的过表达。
稳定性: 稳表达组成型: 组成型病毒/非病毒: 慢病毒pLVX-IRES-Neo载体质粒图谱和多克隆位点信息:pLVX-IRES-Neo载体序列:ORIGIN1 TGGAAGGGCT AATTCACTCC CAAAGAAGAC AAGATATCCT TGATCTGTGG ATCTACCACA61 CACAAGGCTA CTTCCCTGAT TAGCAGAACT ACACACCAGG GCCAGGGGTC AGATATCCAC121 TGACCTTTGG ATGGTGCTAC AAGCTAGTAC CAGTTGAGCC AGATAAGGTA GAAGAGGCCA 181 ATAAAGGAGA GAACACCAGC TTGTTACACC CTGTGAGCCT GCATGGGATG GATGACCCGG 241 AGAGAGAAGT GTTAGAGTGG AGGTTTGACA GCCGCCTAGC ATTTCATCAC GTGGCCCGAG 301 AGCTGCATCC GGAGTACTTC AAGAACTGCT GATATCGAGC TTGCTACAAG GGACTTTCCG 361 CTGGGGACTT TCCAGGGAGG CGTGGCCTGG GCGGGACTGG GGAGTGGCGA GCCCTCAGAT 421 CCTGCATATA AGCAGCTGCT TTTTGCCTGT ACTGGGTCTC TCTGGTTAGA CCAGATCTGA481 GCCTGGGAGC TCTCTGGCTA ACTAGGGAAC CCACTGCTTA AGCCTCAATA AAGCTTGCCT 541 TGAGTGCTTC AAGTAGTGTG TGCCCGTCTG TTGTGTGACT CTGGTAACTA GAGATCCCTC601 AGACCCTTTT AGTCAGTGTG GAAAATCTCT AGCAGTGGCG CCCGAACAGG GACTTGAAAG 661 CGAAAGGGAA ACCAGAGGAG CTCTCTCGAC GCAGGACTCG GCTTGCTGAA GCGCGCACGG 721 CAAGAGGCGA GGGGCGGCGA CTGGTGAGTA CGCCAAAAAT TTTGACTAGC GGAGGCTAGA 781 AGGAGAGAGA TGGGTGCGAG AGCGTCAGTA TTAAGCGGGG GAGAATTAGA TCGCGATGGG 841 AAAAAATTCG GTTAAGGCCA GGGGGAAAGA AAAAATATAA ATTAAAACAT ATAGTATGGG 901 CAAGCAGGGA GCTAGAACGA TTCGCAGTTA ATCCTGGCCT GTTAGAAACA TCAGAAGGCT 961 GTAGACAAAT ACTGGGACAG CTACAACCAT CCCTTCAGAC AGGATCAGAA GAACTTAGAT 1021 CATTATATAA TACAGTAGCA ACCCTCTATT GTGTGCATCA AAGGATAGAG ATAAAAGACA 1081 CCAAGGAAGC TTTAGACAAG ATAGAGGAAG AGCAAAACAA AAGTAAGACC ACCGCACAGC 1141 AAGCGGCCGG CCGCTGATCT TCAGACCTGG AGGAGGAGAT ATGAGGGACA ATTGGAGAAG 1201 TGAATTATAT AAATATAAAG TAGTAAAAAT TGAACCATTA GGAGTAGCAC CCACCAAGGC 1261 AAAGAGAAGA GTGGTGCAGA GAGAAAAAAG AGCAGTGGGA ATAGGAGCTT TGTTCCTTGG 1321 GTTCTTGGGA GCAGCAGGAA GCACTATGGG CGCAGCGTCA ATGACGCTGA CGGTACAGGC 1381 CAGACAATTA TTGTCTGGTA TAGTGCAGCA GCAGAACAAT TTGCTGAGGG CTATTGAGGC 1441 GCAACAGCAT CTGTTGCAAC TCACAGTCTG GGGCATCAAG CAGCTCCAGG CAAGAATCCT1501 GGCTGTGGAA AGATACCTAA AGGATCAACA GCTCCTGGGG ATTTGGGGTT GCTCTGGAAA 1561 ACTCATTTGC ACCACTGCTG TGCCTTGGAA TGCTAGTTGG AGTAATAAAT CTCTGGAACA 1621 GATTTGGAAT CACACGACCT GGATGGAGTG GGACAGAGAA ATTAACAATT ACACAAGCTT 1681 AATACACTCC TTAATTGAAG AATCGCAAAA CCAGCAAGAA AAGAATGAAC AAGAATTATT 1741 GGAATTAGAT AAATGGGCAA GTTTGTGGAA TTGGTTTAAC ATAACAAATT GGCTGTGGTA 1801 TATAAAATTA TTCATAATGA TAGTAGGAGG CTTGGTAGGT TTAAGAATAG TTTTTGCTGT 1861 ACTTTCTATA GTGAATAGAG TTAGGCAGGG ATATTCACCA TTATCGTTTC AGACCCACCT 1921 CCCAACCCCG AGGGGACCCG ACAGGCCCGA AGGAATAGAA GAAGAAGGTG GAGAGAGAGA 1981 CAGAGACAGA TCCATTCGAT TAGTGAACGG ATCTCGACGG TATCGCCTTT AAAAGAAAAG 2041 GGGGGATTGG GGGGTACAGT GCAGGGGAAA GAATAGTAGA CATAATAGCA ACAGACATAC 2101 AAACTAAAGA ATTACAAAAA CAAATTACAA AAATTCAAAA TTTTCGGGTT TATTACAGGG 2161 ACAGCAGAGA TCCAGTTTAT CGATAAGCTT GGGAGTTCCG CGTTACATAA CTTACGGTAA 2221 ATGGCCCGCC TGGCTGACCG CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG 2281 TTCCCATAGT AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT 2341 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 2401 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA TGGGACTTTC 2461 CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC CATGGTGATG CGGTTTTGGC 2521 AGTACATCAA TGGGCGTGGA TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA 2581 TTGACGTCAA TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA 2641 ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 2701 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC TGTTTTGACC 2761 TCCATAGAAG ACACCGACTC TACTAGAGGA TCTATTTCCG GTGAATTCCT CGAGACTAGT 2821 TCTAGAGCGG CCGCGGATCC CGCCCCTCTC CCTCCCCCCC CCCTAACGTT ACTGGCCGAA 2881 GCCGCTTGGA ATAAGGCCGG TGTGCGTTTG TCTATATGTT ATTTTCCACC ATATTGCCGT 2941 CTTTTGGCAA TGTGAGGGCC CGGAAACCTG GCCCTGTCTT CTTGACGAGC ATTCCTAGGG 3001 GTCTTTCCCC TCTCGCCAAA GGAATGCAAG GTCTGTTGAA TGTCGTGAAG GAAGCAGTTC 3061 CTCTGGAAGC TTCTTGAAGA CAAACAACGT CTGTAGCGAC CCTTTGCAGG CAGCGGAACC 3121 CCCCACCTGG CGACAGGTGC CTCTGCGGCC AAAAGCCACG TGTATAAGAT ACACCTGCAA 3181 AGGCGGCACA ACCCCAGTGC CACGTTGTGA GTTGGATAGT TGTGGAAAGA GTCAAATGGC 3241 TCTCCTCAAG CGTATTCAAC AAGGGGCTGA AGGATGCCCA GAAGGTACCC CATTGTATGG 3301 GATCTGATCT GGGGCCTCGG TGCACATGCT TTACATGTGT TTAGTCGAGG TTAAAAAAAC 3361 GTCTAGGCCC CCCGAACCAC GGGGACGTGG TTTTCCTTTG AAAAACACGA TGATAAGCTT 3421 GCCACAACCA TGGCTGAACA AGATGGATTG CACGCAGGTT CTCCGGCCGC TTGGGTGGAG 3481 AGGCTATTCG GCTATGACTG GGCACAACAG ACAATCGGCT GCTCTGATGC CGCCGTGTTC 3541 CGGCTGTCAG CGCAGGGGCG CCCGGTTCTT TTTGTCAAGA CCGACCTGTC CGGTGCCCTG 3601 AATGAACTGC AGGACGAGGC AGCGCGGCTA TCGTGGCTGG CCACGACGGG CGTTCCTTGC 3661 GCAGCTGTGC TCGACGTTGT CACTGAAGCG GGAAGGGACT GGCTGCTATT GGGCGAAGTG 3721 CCGGGGCAGG ATCTCCTGTC ATCTCACCTT GCTCCTGCCG AGAAAGTATC CATCATGGCT 3781 GATGCAATGC GGCGGCTGCA TACGCTTGAT CCGGCTACCT GCCCATTCGA CCACCAAGCG 3841 AAACATCGCA TCGAGCGAGC ACGTACTCGG ATGGAAGCCG GTCTTGTCGA TCAGGATGAT 3901 CTGGACGAAG AGCATCAGGG GCTCGCGCCA GCCGAACTGT TCGCCAGGCT CAAGGCGCGC 3961 ATGCCCGACG GCGAGGATCT CGTCGTGACC CATGGCGATG CCTGCTTGCC GAATATCATG 4021 GTGGAAAATG GCCGCTTTTC TGGATTCATC GACTGTGGCC GGCTGGGTGT GGCGGACCGC 4081 TATCAGGACA TAGCGTTGGC TACCCGTGAT ATTGCTGAAG AGCTTGGCGG CGAATGGGCT4141 GACCGCTTCC TCGTGCTTTA CGGTATCGCC GCTCCCGATT CGCAGCGCAT CGCCTTCTAT 4201 CGCCTTCTTG ACGAGTTCTT CTGAACGCGT CTGGAACAAT CAACCTCTGG ATTACAAAAT 4261 TTGTGAAAGA TTGACTGGTA TTCTTAACTA TGTTGCTCCT TTTACGCTAT GTGGATACGC 4321 TGCTTTAATG CCTTTGTATC ATGCTATTGC TTCCCGTATG GCTTTCATTT TCTCCTCCTT4381 GTATAAATCC TGGTTGCTGT CTCTTTATGA GGAGTTGTGG CCCGTTGTCA GGCAACGTGG 4441 CGTGGTGTGC ACTGTGTTTG CTGACGCAAC CCCCACTGGT TGGGGCATTG CCACCACCTG 4501 TCAGCTCCTT TCCGGGACTT TCGCTTTCCC CCTCCCTATT GCCACGGCGG AACTCATCGC 4561 CGCCTGCCTT GCCCGCTGCT GGACAGGGGC TCGGCTGTTG GGCACTGACA ATTCCGTGGT 4621 GTTGTCGGGG AAGCTGACGT CCTTTCCATG GCTGCTCGCC TGTGTTGCCA CCTGGATTCT 4681 GCGCGGGACG TCCTTCTGCT ACGTCCCTTC GGCCCTCAAT CCAGCGGACC TTCCTTCCCG 4741 CGGCCTGCTG CCGGCTCTGC GGCCTCTTCC GCGTCTTCGC CTTCGCCCTC AGACGAGTCG 4801 GATCTCCCTT TGGGCCGCCT CCCCGCCTGG AATTAATTCT GCAGTCGAGA CCTAGAAAAA 4861 CATGGAGCAA TCACAAGTAG CAATACAGCA GCTACCAATG CTGATTGTGC CTGGCTAGAA 4921 GCACAAGAGG AGGAGGAGGT GGGTTTTCCA GTCACACCTC AGGTACCTTT AAGACCAATG 4981 ACTTACAAGG CAGCTGTAGA TCTTAGCCAC TTTTTAAAAG AAAAGAGGGG ACTGGAAGGG 5041 CTAATTCACT CCCAACGAAG ACAAGATATC CTTGATCTGT GGATCTACCA CACACAAGGC 5101 TACTTCCCTG ATTAGCAGAA CTACACACCA GGGCCAGGGG TCAGATATCC ACTGACCTTT 5161 GGATGGTGCT ACAAGCTAGT ACCAGTTGAG CCAGATAAGG TAGAAGAGGC CAATAAAGGA 5221 GAGAACACCA GCTTGTTACA CCCTGTGAGC CTGCATGGGA TGGATGACCC GGAGAGAGAA 5281 GTGTTAGAGT GGAGGTTTGA CAGCCGCCTA GCATTTCATC ACGTGGCCCG AGAGCTGCAT 5341 CCGGAGTACT TCAAGAACTG CTGATATCGA GCTTGCTACA AGGGACTTTC CGCTGGGGAC 5401 TTTCCAGGGA GGCGTGGCCT GGGCGGGACT GGGGAGTGGC GAGCCCTCAG ATCCTGCATA 5461 TAAGCAGCTG CTTTTTGCCT GTACTGGGTC TCTCTGGTTA GACCAGATCT GAGCCTGGGA 5521 GCTCTCTGGC TAACTAGGGA ACCCACTGCT TAAGCCTCAA TAAAGCTTGC CTTGAGTGCT 5581 TCAAGTAGTG TGTGCCCGTC TGTTGTGTGA CTCTGGTAAC TAGAGATCCC TCAGACCCTT 5641 TTAGTCAGTG TGGAAAATCT CTAGCAGTAG TAGTTCATGT CATCTTATTA TTCAGTATTT 5701 ATAACTTGCA AAGAAATGAA TATCAGAGAG TGAGAGGCCT TGACATTGCT AGCGTTTACC 5761 GTCGACCTCT AGCTAGAGCT TGGCGTAATC ATGGTCATAG CTGTTTCCTG TGTGAAATTG 5821 TTATCCGCTC ACAATTCCAC ACAACATACG AGCCGGAAGC ATAAAGTGTA AAGCCTGGGG 5881 TGCCTAATGA GTGAGCTAAC TCACATTAAT TGCGTTGCGC TCACTGCCCG CTTTCCAGTC 5941 GGGAAACCTG TCGTGCCAGC TGCATTAATG AATCGGCCAA CGCGCGGGGA GAGGCGGTTT 6001 GCGTATTGGG CGCTCTTCCG CTTCCTCGCT CACTGACTCG CTGCGCTCGG TCGTTCGGCT 6061 GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG TTATCCACAG AATCAGGGGA 6121 TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG GCCAGGAACC GTAAAAAGGC 6181 CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC GAGCATCACA AAAATCGACG 6241 CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA TACCAGGCGT TTCCCCCTGG 6301 AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT ACCGGATACC TGTCCGCCTT 6361 TCTCCCTTCG GGAAGCGTGG CGCTTTCTCA TAGCTCACGC TGTAGGTATC TCAGTTCGGT 6421 GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC CCCGTTCAGC CCGACCGCTG 6481 CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGGTA AGACACGACT TATCGCCACT 6541 GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT GTAGGCGGTG CTACAGAGTT 6601 CTTGAAGTGG TGGCCTAACT ACGGCTACAC TAGAAGAACA GTATTTGGTA TCTGCGCTCT 6661 GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT TGATCCGGCA AACAAACCAC 6721 CGCTGGTAGC GGTGGTTTTT TTGTTTGCAA GCAGCAGATT ACGCGCAGAA AAAAAGGATC6781 TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT CAGTGGAACG AAAACTCACG6841 TTAAGGGATT TTGGTCATGA GATTATCAAA AAGGATCTTC ACCTAGATCC TTTTAAATTA6901 AAAATGAAGT TTTAAATCAA TCTAAAGTAT ATATGAGTAA ACTTGGTCTG ACAGTTACCA6961 ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA TTTCGTTCAT CCATAGTTGC7021 CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC TTACCATCTG GCCCCAGTGC7081 TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT TTATCAGCAA TAAACCAGCC7141 AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTTA TCCGCCTCCA TCCAGTCTAT7201 TAATTGTTGC CGGGAAGCTA GAGTAAGTAG TTCGCCAGTT AATAGTTTGC GCAACGTTGT7261 TGCCATTGCT ACAGGCATCG TGGTGTCACG CTCGTCGTTT GGTATGGCTT CATTCAGCTC7321 CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCCATG TTGTGCAAAA AAGCGGTTAG7381 CTCCTTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC GCAGTGTTAT CACTCATGGT7441 TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC GTAAGATGCT TTTCTGTGAC7501 TGGTGAGTAC TCAACCAAGT CATTCTGAGA ATAGTGTATG CGGCGACCGA GTTGCTCTTG7561 CCCGGCGTCA ATACGGGATA ATACCGCGCC ACATAGCAGA ACTTTAAAAG TGCTCATCAT7621 TGGAAAACGT TCTTCGGGGC GAAAACTCTC AAGGATCTTA CCGCTGTTGA GATCCAGTTC7681 GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT TTTACTTTCA CCAGCGTTTC7741 TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAAG GGAATAAGGG CGACACGGAA7801 ATGTTGAATA CTCATACTCT TCCTTTTTCA ATATTATTGA AGCATTTATC AGGGTTATTG7861 TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT AAACAAATAG GGGTTCCGCG7921 CACATTTCCC CGAAAAGTGC CACCTGACGT CGACGGATCG GGAGATCAAC TTGTTTATTG7981 CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTTT8041 TTTCACTGCA TTCTAGTTGT GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGA8101 TCAACTGGAT AACTCAAGCT AACCAAAATC ATCCCAAACT TCCCACCCCA TACCCTATTA8161 CCACTGCCAA TTACCTGTGG TTTCATTTAC TCTAAACCTG TGATTCCTCT GAATTATTTT8221 CATTTTAAAG AAATTGTATT TGTTAAATAT GTACTACAAA CTTAGTAGT//pLVX-IRES-Neo其他相关慢病毒载体:Tet-pLKO-neo Tet-pLKO-puro pPACKH1-GAGpMD2.G pCMV-dR8.2-dvpr pLKO.1-GFP-shRNA pLKO.1-TRC control pLKO.1-hygro pLKO.1-TRCpCDH-MSCV-MCS-EF1-copGFP pCDH-MSCV-MCS-EF1-copGFP-T2A-Puro FUW-tetO-hOKMSFUW-tetO-hOCT4 FUW-tetO-hSOX2 FUW-tetO-hKLF4FUW pLVX-AcGFP1-N1 pLVX-AcGFP1-C1pLVX-AmCyan1-N1 pLVX-DsRed-Express2-C1 pLVX-DsRed-Express2-N1 pLVX-DsRed-Monomer-N1 pLVX-PAmCherry-C1 pLVX-PAmCherry-N1 pLVX-ZsGreen1-N1 pLVX-IRES-ZsGreen1 pLVX-IRES-mCherry pLVX-mCherry-C1 pLVX-mCherry-N1 pLVX-tdTomato-C1 pLKO.1-puro pLentilox 3.7 pLVX-Tet-On-Advanced pLVX-IRES-Puro pLVX-IRES-Neo pLVX-IRES-HygpLVX-EF1α-DsRed-Monomer-C1 pLVX-EF1α-AcGFP1-N1 pLVX-EF1α-AcGFP1-C1 pLVX-EF1α-mCherry-C1 pLVX-EF1α-IRES-mCherry pLVX-EF1α-IRES-ZsGreen1 pLVX-MetLuc Control pLVX-MetLuc pLVX-Hom-Mem1pLVX-Het-2 pLVX-DD-AcGFP1-Actin pPRIME-TET-GFP-FF3pSIH1-H1-CopGFP pCDH-EF1-MCS-T2A-Puro pCDH-CMV-MCS-EF1-Puro pCDF1-MCS2-EF1-copGFP pLOX-CWBmi1 pLOX-CW-CREpRSV-rev pMDLg-pRRE pLL3.7pLVX-DD-AmCyan1 Control pLVX-DD-AmCyan1 Reporter pLVX-DD-tdTomato Reporter pLVX-DD-tdTomato Control pLVX-PTuner-Green pLVX-CherryPicker2pLVX-TetOne-Puro-Luc pLVX-TetOne pLVX-TetOne-PuropLVX-TetOne-Luc pLVX-rHom-Nuc1 pLVX-rHom-Sec1pLVX-rHom-1 pLVX-Hom-Nuc1 pLVX-Het-Nuc1pLVX-PTuner pLVX-PTuner2 pLVX-DD-ZsGreen1 Reporter pLVX-Het-1 pLVX-CherryPicker Control pLVX-Tet3GpCDH-CMV-MCS-EF1-RFP-T2A-Puro pCDH-CMV-MCS-EF1-Hygro pCDH-CMV-MCS-EF1-Neo pCDH-MCS-T2A-Puro-MSCV pCDH1-MCS2-EF1-copGFP pCDF1-MCS2-EF1-Puro pCDH-EF1-MCS-T2A-copGFP pWPXL pLVX-TRE3G-ZsGreen1 pLVX-TRE3G-mCherry pLenti6.3-EmGFP-BveI miR pLenti6/V5-GW/lacZpLenti6.3/V5-GW/EmGFP pLenti6.3-MCS pLenti6.3-DsRed2-BveI miR pLenti6.3-MCS-IRES2-EGFP pLVX-shRNA2 psPAX2VSV-G pSico PGK Puro pcDNA6.2-DsRed2-MCS1 miR pcDNA6.3-EmGFP-NC- II pcDNA6.2-EmGFP-NC- I pcDNA6.2-EmGFP-BsaI miR pLenti6.3-BveI miR pLenti6.3-MCS-IRES2-DsRed2 pLEX-MCSpGIPZ pLP2 pLP1FUGW pFUGW pLOX-Ttag-iresTKpMDLg/pRRE pLentG-KOSM pCMV-dR8.91pLVX-TRE3G-Luc Control pLVX-TRE3G-IRES pCgpvpSico pSicoR pLVTHMpGensil-1 pLVX-EF1α-IRES-Puro pCDF1-MCS2-EF1-copGFP pPACKH1-REV pLVX-Het-Mem1 pLVX-shRNA1pLKO.1-puro-GFP-siRNA pPRIME-TREX-GFP-FF3 pcDNA6.2-DsRed2-BsmBI miR pCDH-MSCV-MCS-EF1-Puro pCDH-CMV-MCS-EF1-copGFP pLVX-TRE3GFUW-tetO-hMYC pLOX-TERT-iresTK pLP/VSVGFUW-M2rtTA pCDH-EF1-MCS-(PGK-Puro) pcDNA6.2-EmGFP-MCS1 miR pLVX-AmCyan1-C1 pLVX-Hom-1 pcDNA6.2-BsaI miRpLVX-DsRed-Monomer-C1 pLVX-mCherry-Actin pTRIPZpLVX-ZsGreen1-C1 pLVX-CherryPicker1 LeGO-iC2pLVX-IRES-tdTomato pCDH-CMV-MCS-EF1-copGFP-T2A-Puro pLKO.3GpLVX-tdTomato-N1 pLVX-PTuner2-C pLVX-PuropLVX-Tight-Puro pLVX-DD-ZsGreen1 Control pSicoR PGK PuropLVX-EF1α-DsRed-Monomer-N1 pCDH-UbC-MCS-EF1-Hygro pLVTHpLVX-EF1α-mCherry-N1 pCDH-CMV-MCS-EF1-RFP。
pLEX-MCS慢病毒载体使用说明
pLEX-MCS pLEX-MCS载体基本信息:载体名称:pLEXMCS, pLEX MCS, pLEX-MCS质粒类型: 哺乳动物细胞慢病毒表达载体高拷贝/低拷贝: 高拷贝启动子: CMV克隆方法: 多克隆位点,限制性内切酶载体大小: 10682 bp5' 测序引物及序列: pLEX-MCS-FWD: CACCAAAATCAACGGGACTT3' 测序引物及序列: pLEX-MCS-REV: ATATAGACAAACGCACACCGGCCT 载体标签: --载体抗性: 氨苄/博来霉素(Zeocin)筛选标记: 嘌呤霉素(Puromycin)备注:稳定性: 稳定组成型: 诱导型病毒/非病毒: 慢病毒pLEX-MCS载体质粒图谱和多克隆位点信息:pLEX-MCS载体简介:pLEX-MCS载体是慢病毒载体,带有一个多克隆位点。
pLEXMCS载体骨架是设计用来瞬转或稳转表达目的慢病毒,进而感染目的细胞系,导致你的目的基因过表达的载体。
pLEX-MCS载体拥有多个载体特征(具体见上文),这些载体特征使得载体能够有效进行过表达基因研究。
1.具有使用复制的非竞争性慢病毒转染或者转导的能力。
2.在体内和体外使用时都比较容易控制。
3.在进构建稳转细胞系的时候,可以使用嘌呤霉素进行筛选。
4.可以方便将任何目的基因导入到载体的多克隆位点处。
pLEX-MCS载体序列pLEX-MCS其他相关慢病毒载体:Tet-pLKO-neo Tet-pLKO-puro pPACKH1-GAGpMD2.G pCMV-dR8.2-dvpr pLKO.1-GFP-shRNA pLKO.1-TRC control pLKO.1-hygro pLKO.1-TRCpCDH-MSCV-MCS-EF1-copGFP pCDH-MSCV-MCS-EF1-copGFP-T2A-Puro FUW-tetO-hOKMSFUW-tetO-hOCT4 FUW-tetO-hSOX2 FUW-tetO-hKLF4FUW pLVX-AcGFP1-N1 pLVX-AcGFP1-C1pLVX-AmCyan1-N1 pLVX-DsRed-Express2-C1 pLVX-DsRed-Express2-N1 pLVX-DsRed-Monomer-N1 pLVX-PAmCherry-C1 pLVX-PAmCherry-N1pLVX-ZsGreen1-N1 pLVX-IRES-ZsGreen1 pLVX-IRES-mCherrypLVX-mCherry-C1 pLVX-mCherry-N1 pLVX-tdTomato-C1 pLKO.1-puro pLentilox 3.7 pLVX-Tet-On-Advanced pLVX-IRES-Puro pLVX-IRES-Neo pLVX-IRES-HygpLVX-EF1α-DsRed-Monomer-C1 pLVX-EF1α-AcGFP1-N1 pLVX-EF1α-AcGFP1-C1 pLVX-EF1α-mCherry-C1 pLVX-EF1α-IRES-mCherry pLVX-EF1α-IRES-ZsGreen1 pLVX-MetLuc Control pLVX-MetLuc pLVX-Hom-Mem1pLVX-Het-2 pLVX-DD-AcGFP1-Actin pPRIME-TET-GFP-FF3pSIH1-H1-CopGFP pCDH-EF1-MCS-T2A-Puro pCDH-CMV-MCS-EF1-Puro pCDF1-MCS2-EF1-copGFP pLOX-CWBmi1 pLOX-CW-CREpRSV-rev pMDLg-pRRE pLL3.7pLVX-DD-AmCyan1 Control pLVX-DD-AmCyan1 Reporter pLVX-DD-tdTomato Reporter pLVX-DD-tdTomato Control pLVX-PTuner-Green pLVX-CherryPicker2pLVX-TetOne-Puro-Luc pLVX-TetOne pLVX-TetOne-PuropLVX-TetOne-Luc pLVX-rHom-Nuc1 pLVX-rHom-Sec1pLVX-rHom-1 pLVX-Hom-Nuc1 pLVX-Het-Nuc1pLVX-PTuner pLVX-PTuner2 pLVX-DD-ZsGreen1 Reporter pLVX-Het-1 pLVX-CherryPicker Control pLVX-Tet3GpCDH-CMV-MCS-EF1-RFP-T2A-Puro pCDH-CMV-MCS-EF1-Hygro pCDH-CMV-MCS-EF1-Neo pCDH-MCS-T2A-Puro-MSCV pCDH1-MCS2-EF1-copGFP pCDF1-MCS2-EF1-Puro pCDH-EF1-MCS-T2A-copGFP pWPXL pLVX-TRE3G-ZsGreen1 pLVX-TRE3G-mCherry pLenti6.3-EmGFP-BveI miR pLenti6/V5-GW/lacZpLenti6.3/V5-GW/EmGFP pLenti6.3-MCS pLenti6.3-DsRed2-BveI miR pLenti6.3-MCS-IRES2-EGFP pLVX-shRNA2 psPAX2VSV-G pSico PGK Puro pcDNA6.2-DsRed2-MCS1 miR pcDNA6.3-EmGFP-NC- II pcDNA6.2-EmGFP-NC- I pcDNA6.2-EmGFP-BsaI miR pLenti6.3-BveI miR pLenti6.3-MCS-IRES2-DsRed2 pLEX-MCSpGIPZ pLP2 pLP1FUGW pFUGW pLOX-Ttag-iresTKpMDLg/pRRE pLentG-KOSM pCMV-dR8.91pLVX-TRE3G-Luc Control pLVX-TRE3G-IRES pCgpvpSico pSicoR pLVTHMpGensil-1 pLVX-EF1α-IRES-Puro pCDF1-MCS2-EF1-copGFP pPACKH1-REV pLVX-Het-Mem1 pLVX-shRNA1pLKO.1-puro-GFP-siRNA pPRIME-TREX-GFP-FF3 pcDNA6.2-DsRed2-BsmBI miR pCDH-MSCV-MCS-EF1-Puro pCDH-CMV-MCS-EF1-copGFP pLVX-TRE3GFUW-tetO-hMYC pLOX-TERT-iresTK pLP/VSVGFUW-M2rtTA pCDH-EF1-MCS-(PGK-Puro) pcDNA6.2-EmGFP-MCS1 miR pLVX-AmCyan1-C1 pLVX-Hom-1 pcDNA6.2-BsaI miRpLVX-DsRed-Monomer-C1 pLVX-mCherry-Actin pTRIPZpLVX-ZsGreen1-C1 pLVX-CherryPicker1 LeGO-iC2pLVX-IRES-tdTomato pCDH-CMV-MCS-EF1-copGFP-T2A-Puro pLKO.3GpLVX-tdTomato-N1 pLVX-PTuner2-C pLVX-PuropLVX-Tight-Puro pLVX-DD-ZsGreen1 Control pSicoR PGK PuropLVX-EF1α-DsRed-Monomer-N1 pCDH-UbC-MCS-EF1-Hygro pLVTHpLVX-EF1α-mCherry-N1 pCDH-CMV-MCS-EF1-RFP。
慢病毒转染手册
慢病毒(Lentivirus)载体是以HIV-1(人类免疫缺陷I型病毒)为基础发展起来的基因治疗载体。
区别一般的逆转录病毒载体,它对分裂细胞和非分裂细胞均具有感染能力。
基本概述慢病毒载体的研究发展得很快,研究的也非常深入。
该载体可以将外源基因有效地整合到宿主染色体上,从而达到持久性表达。
在感染能力方面可有效地感染神经元细胞、肝细胞、心肌细胞、肿瘤细胞、内皮细胞、干细胞等多种类型的细胞,从而达到良好的的基因治疗效果,在美国已经开展了临床研究,效果非常理想,因此具有广阔的应用前景。
慢病毒的应用目前慢病毒也被广泛地应用于表达RNAi的研究中。
由于有些类型细胞脂质体转染效果差,转移到细胞内的siRNA半衰期短,体外合成siRNA对基因表达的抑制作用通常是短暂的,因而使其应用受到较大的限制。
采用事先在体外构建能够表达siRNA的载体, 然后转移到细胞内转录siRNA的策略,不但使脂质体有效转染的细胞种类增加,而且对基因表达抑制效果也不逊色于体外合成siRNA,在长期稳定表达载体的细胞中,甚至可以发挥长期阻断基因表达的作用。
在所构建的siRNA表达载体中,是由RNA聚合酶Ⅲ启动子来指导RNA合成的,这是因为RNA聚合酶Ⅲ有明确的起始和终止序列,而且合成的RNA不会带poly A尾。
当RNA聚合酶Ⅲ遇到连续4个或5个T时,它指导的转录就会停止,在转录产物3’端形成1~4个U。
U6和H1 RNA启动子是两种RNA聚合酶Ⅲ依赖的启动子,其特点是启动子自身元素均位于转录区的上游,适合于表达~21ntRNA和~50ntRNA茎环结构(stem loop)。
在siRNA表达载体中,构成siRNA的正义与反义链,可由各自的启动子分别转录,然后两条链互补结合形成siRNA;也可由载体直接表达小发卡状RNA(small hairpin RNA, shRNA), 载体包含位于RNA聚合酶Ⅲ启动子和4~5T转录终止位点之间的茎环结构序列,转录后即可折叠成具有1~4 个U 3 ’ 突出端的茎环结构,在细胞内进一步加工成siRNA。
慢病毒使用操作手册
慢病毒使用操作手册:1 慢病毒使用操作2 慢病毒安全使用规范3 悬浮细胞感染方法概要4 相关专业术语(详情可参考公司网站FAQ)5 细胞培养器皿的相关参数1、慢病毒使用操作手册1.1 慢病毒的储存与稀释:1.1.1 病毒的储存:用户收到病毒液后在很短时间内即使用慢病毒进行实验,可以将病毒暂时放置于4 ℃保存;如需长期保存请放置于-80℃(病毒置于冻存管,并使用封口膜封口)A.病毒可以存放于-80℃ 6个月以上;但如果病毒储存时间超过6个月,我们建议在使用前需要重新滴定病毒滴度B.反复冻融会降低病毒滴度:每次冻融会降低病毒滴度10%;因此在病毒使用过程中应仅尽量避免反复冻融,为避免反复冻融我们强烈建议客户收到病毒后按照每次的使用量进行分装。
1.1.2 病毒的稀释:用户需要稀释病毒时,请将病毒取出置于冰浴融解后,使用培养目的细胞用PBS或无血清培养基(含血清或含双抗不影响病毒感染)混匀分装后4℃保存(请尽量在三天内用完) 分装后使用。
1.2 慢病毒用于体外(In Vitro)实验:感染培养原代细胞和建系细胞1.2.1 慢病毒对各种细胞和组织的亲嗜性不同,用户使用Invabio提供的慢病毒之前可以通过查阅相关文献,了解慢病毒对您的目的细胞的亲嗜性,感染复数(MOI 值)以及在体(In Vivo)注射所需要的病毒量。
如果没有相关文献支持,可以通过感染预实验得到合适的感染复数(MOI 值)(使用24孔板检测病毒对目的细胞的亲嗜性)1.2.2 慢病毒感染目的细胞预实验1.2.2.1 慢病毒感染目的细胞预实验注意事项A.测定慢病毒对目的细胞的亲嗜性时,需要同时设置对慢病毒亲嗜性较高的细胞(HEK293T,Hela)作为平行实验的对照细胞。
B.在进行慢病毒感染实验时,可以用完全培养基(培养目的细胞用)稀释;理论上,含有血清,双抗或者其他营养因子的完全培养基不影响慢病毒的感染效率。
C. Invabio提供的病毒单位为TU/ml, 即每毫升中含有具有生物活性的病毒颗粒数。
pPACKH1-GAG慢病毒载体使用说明
pPACKH1-GAGpPACKH1-GAG 载体基本信息:载体名称:pPACKH1-GAG 质粒类型: 慢病毒包装载体 高拷贝/低拷贝: 高拷贝 克隆方法: 限制性内切酶,多克隆位点启动子:CMV 载体大小:11.1kb 5' 测序引物及序列: CMV Forward : CGCAAATGGGCGGTAGGCGTG3' 测序引物及序列:-- 载体标签:-- 载体抗性: 氨苄青霉素筛选标记:-- 克隆菌株: TOP10、DH5a 等感受态细胞宿主细胞(系):293T备注第三代慢毒包装载体pPACKH1-GAG 与pPACKH1-REV,pVSV-G 是基于HIV-1的慢病毒包装系统。
用于第三代慢病毒载体的包装,如: pCDH-CMV-MCS-EF1-puro pCDH-CMV-MCS-EF1-copGFP pCDH-CMV-MCS-EF1-copGFP-T2A-puro pCDH-CMV-MCS-EF1-RFP pCDH-MCS-T2A-puro-MSCV稳定性: 瞬表达 组成型/诱导型: 组成型 病毒/非病毒: 非病毒pPACKH1-GAG 载体质粒图谱和多克隆位点信息:pPACKH1-GAG载体简介:慢病毒包装与转染方法——第三代慢病毒包装载体pPACKH1-GAG使用方法:Production of lentiviral viral stocks requires HIV-1 gag, pol, and rev gene products and vesicular stomatitis virus G (VSV-G) protein encoded by helper plasmids. In general, at least two helper plasmids are required, with one plasmid expressing the Gag-Pol polyprotein and an accessory protein Rev and the other expressing VSV-G as envelop protein to increase cell tropism. Nevertheless, Gag-Pol and Rev proteins can be expressed from separated plasmids as well. Therefore, a three-plasmid system or a four-plasmid system can be used to generate viral stocks, depending on the source and nature of the helper plasmids. In the three-plasmid system, lentiviral transfer vector is cotransfected with two helper plasmids (Gag-Pol + Rev and VSV-G) into cells, while in the four-plasmid system; lentiviral transfer vector is cotransfected with three helper plasmids (Gag-Pol, Rev and VSV-G). It is generally considered to be safer to produce the lentiviral stocks with more helper plasmids, due to the reduced chance of recombination among all vectors that generates replication-competent viruses. The manufacturers of transfection reagents, the suppliers of lentiviral packaging constructs, and many academic laboratories have provided protocols for producing lentiviral stocks. The following procedure is provided as an example only. We produce lentiviral stocks in 293T cellsBelow we have listed the commonly used vectors for lentiviral packaging.1 For example: pCMV-deltaR8.91 (TRC), psPAX2 (Addgene)2 For example: pMDLg/pRRE (Addgene), pLP1 (Invitrogen), pPACKH1-GAG (SBI)3 For example: pRSV-REV (Addgene), pLP2 (Invitrogen), pPACKH1-REV (SBI)4 For example: pMD.G (TRC), pMD2.G (Addgene), pCMV-VSV-G (Addgene), pVSV-G (SBI),pLP/VSVG (Invitrogen)Note: The transfection reagent Lipofectamine™ 2000 (LF2000, Invitrogen) is preferred for transfection. The average lentiviral titers in our preparations are around 5 x 106 - 5 x 107 infection units per ml (IU/ml) when titered with 293T cells.Day 0: Seed 6.0 × 106 (1.0 × 106) 293T cells in a 10-cm plate (6-well plate), so that the cell density will be around 1.0 × 107 (1.7 × 106) at the time of transduction.Day 1: Gently mix 45.0 (7.5) μl LF2000 and 1.5 (0.25) ml Opti-MEM medium and incubate at room tempera ture for 5 minutes. Meanwhile, gently mix 18.0 (3.0) μg in total of lentiviral transfer vector and helper plasmids mixture into 1.5 (0.25) ml Opti-MEM medium (Invitrogen).Gently mix DNA and LF2000, incubate at room temperature for 20 minutes to allow DNA and lipid to form complexes. In the meantime, replace the overnight culture medium with 5.0 (1.0) ml DMEM + 10% FBS without antibiotics. Add the 3.0 (0.5) ml DNA-LF2000 complexes to 293T cells.Note: We have noticed that fetal bovine serum purchased from different manufacturers may affect the attachment of 293T cells to the bottom of tissue culture plates, resulting in variation in the efficiency of lentiviral production. We recommend switching to a different brand of FBS if 293T cells disattach from plates during lentiviral production.Day 2: Replace the media containing the DNA-LF2000 complexes with 10.0 (2.0) ml complete medium at 12-16 hours post-transfection.Day4: Collect supernatants at 48 hours post-transfection and transfer media to a polypropylene storage tube. Spin the virus-containing media at 1300 rpm for 5 minutes to pellet any 293T cells that were carried over during collection. Carefully transfer the supernatant to a sterile polypropylene storage tube.Note: Lentiviral stock may be stored at 4 °C for up to 5 days, but should be aliquoted and frozen at -80 °C for long-term storage.Suggestion: To reduce the number of freeze and thaw cycles, aliquot lentiviral stock to smaller tubes before storage at -80 °C.Titering the lentiviral stocksIt is important to titer the lentiviral stocks in the cell line of interest to produce consistent results using the equivalent multiplicity of infection (MOI) in experiments. Knowing MOI will help you to control the copy number of lenti-cDNA integrated into the chromosomes of the cells of interest. While titering virus with antibiotic selection, the titering procedure includes selection of stably transduced cells with the corresponding antibiotics and counting the antibiotic-resistant cell colonies. Alternatively, a flow cytometry can be used to determine the viral titer by measuring the number of green (or red) fluorescent cells. If you are using both methods to titer your lentiviruses, please keep in mind that the titers may be different due to sensitivities of FACS machine and cell lines resistant to drug selection.Please be aware the lenti-cDNA virus titer may be underestimated when antibiotic selectionor flow cytometry is deployed to determine the titer. For example, the transduced cells with single integration event may not be selected due to low level of selection marker expressionby IRES.A. Determination of lentiviral titers by antibiotics selection.Day 0: Seed the cells of your choice in a 6-well plate so that the cell density that will be ~25-50% confluent at the time of transduction.Day 1: Thaw lentiviral stock, gently mix virus and then prepare 2 ml 10-fold serial dilutions ranging from 10-3 to 10-7 in complete medium containing 5-8 μg/ml polybrene.Remove the medium from previous day and add 2 ml fresh dilutions into each well. Suggestion: Leave one well uninfected for mock control. Spin transduction in a desktop centrifuge (e.g. Sorvall RT6000) at 1,000 × g for 30-60 min at room temperature may be necessary if titering virus in cell lines other than 293T.Day 2: Replace the medium containing virus and polybrene with 2 ml of complete medium.Day 3-4: Replace medium with fresh medium containing antibiotic to select for stably transduced cells.Note: At least 48 hours of transduction allows lenti-cDNA to integrate into the host genome. The optimal antibiotic concentration varies from cell line to cell line.Suggestion: A pilot experiment should be performed to determine the minimum concentration of antibiotics required to kill the untransduced cells before this experiment.Day 5-6: Replace medium with 2 ml fresh medium containing antibiotic every 2 days.Day 7-8: Allow antibiotic-resistant colonies to form in dilution wells. No live cells should be growing in the mock control well.Note: The number of days required for the formation of visible colonies may vary among different cell lines.Wash wells twice with 2 ml PBSStain cells with 1 ml 0.5% crystal violet solution in 20% ethanol and incubate for 30 minutes at room temperature.Wash wells with distilled water by submerging the plate in a tray full of water, and repeat the wash one more time.Dry the plate and count the number of blue-stained colonies.The titer should be the average colony number times the dilution factor.Note: The transduction efficiency varies from cell line to cell line. The lentiviral titer in the cell line of your interest may be lower (sometimes more than 10-fold) or higher than the virustiter in commonly used cell lines such as 293T cells.B. Determination of lentiviral titers by flow cytometry.Day 0: Seed the cell of your choice in a 6-well plate so that the cell density that will be ~25-50% confluent at the time of transduction.Note: The number of cells seeded in the well is required to calculate lentiviral titer later.Day 1: Thaw lentiviral stock, gently mix virus and then prepare 2 ml 10-fold serial dilutions ranging from 10-1 to 10-4 in complete medium containing 5-8 μg/ml polybrene.Remove the medium from previous day and add 2 ml fresh dilutions into each well.Suggestion: Leave one well uninfected for mock control. Spin transduction in a desktop centrifuge (e.g. Sorvall RT6000) at 1,000 × g for 30-60 min at room temperature may be necessary if titering virus in cell lines other than 293T.Day 2: Replace the medium containing virus and polybrene with 2 ml of complete medium.Day 3-4: Follow your lab protocol to collect and resuspend cells for flow cytometry to determine the percentage of green or red fluorescent cells.Note: At least 48 hours of transduction allows lenti-cDNA to integrate into the host genome. The titer should be the average number of live fluorescent cells times the dilution factor.Note: The transduction efficiency varies from cell line to cell line. The lentiviral titer in the cell line of your interest may be lower (sometimes more than 10-fold) or higher than the virustiter in commonly used cell lines such as 293T cells.Example: 1 × 105 cells were seeded on Day 0 and the cell doubling time is around 24 hours. The FACS data showed 5% and 40% of green fluorescence cells in the 10-3 and 10-2 dilution wells, respectively. The lentiviral titer is calculated by multiplying the fraction of transduced cells by 2 × 105 (the expected number of cells in the well on Day 1, the time of transduction), and by the dilution factor.0.05 × (2 × 105) × 103 = 1 × 1070.4 × (2 × 105) × 102 = 8 × 106The average lentiviral titer is 9 × 106 IU/mlLentiviral Transduction for Gene Expression.Day 0: Seed cells at appropriate density.Suggestion: Plate cells so that cell density will be ~10-25% confluent at the time of transduction.Day 1: Transduction. Remove the medium from the tissue culture plate by aspiration and replace it with fresh complete medium containing 5-8 μg/ml polybrene. Gently mix lentivirus with pipette tip, and add appropriate amount of virus to each well.Note: (1) Polybrene may be toxic to some cell lines. (2) The non-concentrated andnon-purified lentiviral stock collected from 293T supernatant may contain substances affecting the target cell growth, especially when a large volume of low-titer lentiviral stock is added. In case the lentiviral stock inhibits cell growth, concentration and purification of the viruses may be required. (See below for a protocol of virus concentration) Alternatively, incubation time for transduction can be shortened to hours. For example, the virus-containing medium may be replaced with fresh medium after one hour of transduction. Suggestion: Transduce cells at multiplicity of infection (MOI) = 1, 5, 10, 25, and 50 to determine the optimal expression level. Spin transduction in a desktop centrifuge (e.g. Sorvall RT6000) at 1,000 × g for 30-60 min at room temperature helps increase of transduction efficiency.Day 2: Replace the transduction medium with fresh complete medium to remove lentivirus and polybrene.Day 3-4: Select transduced cells (>50% confluence is recommended) with medium containing appropriate antibiotics or by flow cytometry to sort out fluorescence-positive cells if necessary.Note: The optimal antibiotic concentration varies from cell line to cell line.Suggestion: A pilot experiment should be performed to determine the minimum concentration of antibiotic required to kill the untransduced cells before this experiment.Day 6+: Analysis of transduced cells.Suggestion: Expand the culture of cell lines stably expressing GOI and store the cell line stocks in liquid nitrogen before analyzing the cells.Optional: Concentration of lentivirus by ultracentrifugation1. Filter lentivirus through a 0.45 μm filter.2. Centrifuge at 25,000 rpm for 90 minutes in a SW-28 or SW-41 rotor.3. Discard the supernatant and use a Pasteur pipette with an attached P100 tip to carefully remove the remaining medium.4. Gently resuspend viral pellet in 1/100 volume of DMEM. Let the virus suspension sit forovernight at 4° C.5. On the following day, mix gently, aliquot and freeze virus.pPACKH1-GAG载体序列pPACKH1-GAG其他相关慢病毒载体:Tet-pLKO-neo Tet-pLKO-puro pPACKH1-GAGpMD2.G pCMV-dR8.2-dvpr pLKO.1-GFP-shRNA pLKO.1-TRC control pLKO.1-hygro pLKO.1-TRCpCDH-MSCV-MCS-EF1-copGFP pCDH-MSCV-MCS-EF1-copGFP-T2A-Puro FUW-tetO-hOKMSFUW-tetO-hOCT4 FUW-tetO-hSOX2 FUW-tetO-hKLF4FUW pLVX-AcGFP1-N1 pLVX-AcGFP1-C1pLVX-AmCyan1-N1 pLVX-DsRed-Express2-C1 pLVX-DsRed-Express2-N1 pLVX-DsRed-Monomer-N1 pLVX-PAmCherry-C1 pLVX-PAmCherry-N1pLVX-ZsGreen1-N1 pLVX-IRES-ZsGreen1 pLVX-IRES-mCherrypLVX-mCherry-C1 pLVX-mCherry-N1 pLVX-tdTomato-C1 pLKO.1-puro pLentilox 3.7 pLVX-Tet-On-Advanced pLVX-IRES-Puro pLVX-IRES-Neo pLVX-IRES-HygpLVX-EF1α-DsRed-Monomer-C1 pLVX-EF1α-AcGFP1-N1 pLVX-EF1α-AcGFP1-C1 pLVX-EF1α-mCherry-C1 pLVX-EF1α-IRES-mCherry pLVX-EF1α-IRES-ZsGreen1 pLVX-MetLuc Control pLVX-MetLuc pLVX-Hom-Mem1pLVX-Het-2 pLVX-DD-AcGFP1-Actin pPRIME-TET-GFP-FF3pSIH1-H1-CopGFP pCDH-EF1-MCS-T2A-Puro pCDH-CMV-MCS-EF1-Puro pCDF1-MCS2-EF1-copGFP pLOX-CWBmi1 pLOX-CW-CREpRSV-rev pMDLg-pRRE pLL3.7pLVX-DD-AmCyan1 Control pLVX-DD-AmCyan1 Reporter pLVX-DD-tdTomato Reporter pLVX-DD-tdTomato Control pLVX-PTuner-Green pLVX-CherryPicker2pLVX-TetOne-Puro-Luc pLVX-TetOne pLVX-TetOne-PuropLVX-TetOne-Luc pLVX-rHom-Nuc1 pLVX-rHom-Sec1pLVX-rHom-1 pLVX-Hom-Nuc1 pLVX-Het-Nuc1pLVX-PTuner pLVX-PTuner2 pLVX-DD-ZsGreen1 Reporter pLVX-Het-1 pLVX-CherryPicker Control pLVX-Tet3GpCDH-CMV-MCS-EF1-RFP-T2A-Puro pCDH-CMV-MCS-EF1-Hygro pCDH-CMV-MCS-EF1-Neo pCDH-MCS-T2A-Puro-MSCV pCDH1-MCS2-EF1-copGFP pCDF1-MCS2-EF1-Puro pCDH-EF1-MCS-T2A-copGFP pWPXL pLVX-TRE3G-ZsGreen1 pLVX-TRE3G-mCherry pLenti6.3-EmGFP-BveI miR pLenti6/V5-GW/lacZpLenti6.3/V5-GW/EmGFP pLenti6.3-MCS pLenti6.3-DsRed2-BveI miR pLenti6.3-MCS-IRES2-EGFP pLVX-shRNA2 psPAX2VSV-G pSico PGK Puro pcDNA6.2-DsRed2-MCS1 miR pcDNA6.3-EmGFP-NC- II pcDNA6.2-EmGFP-NC- I pcDNA6.2-EmGFP-BsaI miR pLenti6.3-BveI miR pLenti6.3-MCS-IRES2-DsRed2 pLEX-MCSpGIPZ pLP2 pLP1FUGW pFUGW pLOX-Ttag-iresTKpMDLg/pRRE pLentG-KOSM pCMV-dR8.91pLVX-TRE3G-Luc Control pLVX-TRE3G-IRES pCgpvpSico pSicoR pLVTHMpGensil-1 pLVX-EF1α-IRES-Puro pCDF1-MCS2-EF1-copGFP pPACKH1-REV pLVX-Het-Mem1 pLVX-shRNA1pLKO.1-puro-GFP-siRNA pPRIME-TREX-GFP-FF3 pcDNA6.2-DsRed2-BsmBI miR pCDH-MSCV-MCS-EF1-Puro pCDH-CMV-MCS-EF1-copGFP pLVX-TRE3GFUW-tetO-hMYC pLOX-TERT-iresTK pLP/VSVGFUW-M2rtTA pCDH-EF1-MCS-(PGK-Puro) pcDNA6.2-EmGFP-MCS1 miR pLVX-AmCyan1-C1 pLVX-Hom-1 pcDNA6.2-BsaI miRpLVX-DsRed-Monomer-C1 pLVX-mCherry-Actin pTRIPZpLVX-ZsGreen1-C1 pLVX-CherryPicker1 LeGO-iC2pLVX-IRES-tdTomato pCDH-CMV-MCS-EF1-copGFP-T2A-Puro pLKO.3GpLVX-tdTomato-N1 pLVX-PTuner2-C pLVX-PuropLVX-Tight-Puro pLVX-DD-ZsGreen1 Control pSicoR PGK PuropLVX-EF1α-DsRed-Monomer-N1 pCDH-UbC-MCS-EF1-Hygro pLVTHpLVX-EF1α-mCherry-N1 pCDH-CMV-MCS-EF1-RFP。
慢病毒生产及使用操作手册
慢病毒生产及使用操作手册一、实验流程制备慢病毒穿梭质粒及其辅助包装原件载体质粒,三种质粒载体分别进行高纯度无内毒素抽提,共转染293T细胞,转染后6 h 更换为完全培养基,培养48和72h后,分别收集富含慢病毒颗粒的细胞上清液,病毒上清液通过超离心浓缩病毒。
以下内容由汉恒生物科技(上海)有限公司精心整理总结。
二、实验材料(一)慢病毒载体、包装细胞和菌株该病毒包装系统为三质粒系统,组成为pspax2, pMD2G,pHBLV TM系列质粒。
1、载体信息(见附录)2、细胞株 293T,慢病毒的包装细胞,为贴壁依赖型成上皮样细胞,生长培养基为DMEM(含10% FBS)。
贴壁细胞经培养生长增殖形成单层细胞。
3、菌株大肠杆菌菌株DH5α。
用于扩增慢病毒载体和辅助包装载体质粒。
三、包装细胞293T细胞的培养(一) 293T细胞的冻存随着传代的次数增加,293T细胞会出现生长状态下降、突变等。
为了防止此类现象的出现,我们需要在开始就对细胞进行大量冻存,以保证实验的稳定性和持续性。
在细胞对数生长期进行冻存,增加细胞复苏成活率。
1、去掉上清液,加入PBS洗去残留的培养基;2、加入0.25%的胰酶,消化1~2min后,镜下观察细胞变圆,细胞间间隙加大时,去除胰酶,加入新鲜培养基吹打混匀,移入离心管中。
3、细胞计数,将细胞全部晃下,加入 3mL 37 ℃预热的 10% DMEM,用 10mL 移液管进行吹打,较大力吹打 6~8 次即可,不留死角,之后,将所有细胞吸出,置于15mL 离心管中,取 50ul 混匀后的细胞于 1.5mL eppendorf 管中,加入 450ul 10% DMEM,即为 10 倍稀释,混匀,取 10ul 细胞于计数板中计数。
计数板上共 4 大格,每大格 16 小格。
计数时,4 大格均计数,总数除以 4(得每大格细胞数),再乘以 10(10 倍稀释),即为实际 n万/mL 细胞浓度。
4、细胞离心,1000rpm,5min。
金拓思慢病毒产品说明书
金拓思慢病毒产品说明书一、产品简介慢病毒载体是一类重组逆转录病毒载体,由于其结构和功能的特点,慢病毒载体作为一种重要的基因转移工具应用于基因治疗和细胞分子生物学研究领域。
区别于一般的逆转录病毒载体,它对分裂细胞和非分裂细胞均具有感染能力。
该载体可以将外源基因有效地整合到宿主染色体上,从而达到持久性表达。
在感染能力方面可有效地感染神经元细胞、肝细胞、心肌细胞、肿瘤细胞、内皮细胞、干细胞等多种类型细胞,达到良好的基因治疗效果。
我公司生产的重组慢病毒均以国际通用的第三代载体四质粒体系生产,通过重组改造后将含有目的基因的慢病毒骨架及其相应的作用元件组合为新质粒,并通过辅助质粒将病毒包装的元件组成重组病毒。
通过自我灭活的方式,阻止病毒自我复制。
保证了慢病毒使用过程中的良好生物安全性。
二、重要说明2.1安全操作说明1.应在Ⅱ级及以上级别生物安全柜中使用慢病毒产品。
2.虽经过改造后病毒安全性极大提高,操作中仍需佩戴口罩、手套等安全防护措施以免产生潜在危害。
3.操作中所有接触慢病毒试剂的样品、耗材、器皿等均需通过84消毒液(1:20)浸泡后,高温121℃灭活15min以上。
4.实验过程中有病毒液洒落的情况时,应用纸巾将病毒液吸干后喷洒70乙醇,并将擦干的纸巾一并高温处理以免造成其它伤害、污染环境。
2.2使用注意事项所有慢病毒产品均通过干冰低温运输,请收到产品后立即转入-80℃冰箱保存。
每次使用时提前取出病毒液放置在4℃冰箱待融化,并保存于4℃冰箱。
每次融化后请尽快使用,病毒液应尽量避免反复冻融降低病毒滴度。
三、慢病毒制备与使用3.1实验材料细胞:人贴壁细胞293T培养基:高糖DMEM培养基血清:胎牛血清抗生素:青链霉素转染试剂:Transfection-mate增强剂:Polybrene3.2病毒制备方法3.2.1细胞准备细胞复苏:1.将液氮保存细胞取出后,迅速放入37℃水浴锅内,应及时轻柔摇动加快解冻速度。
2.将完全溶解的细胞离心,1500rpm,3min。
慢病毒生产及使用操作手册
慢病毒生产及使用操作手册一、实验流程制备慢病毒穿梭质粒及其辅助包装原件载体质粒,三种质粒载体分别进行高纯度无内毒素抽提,共转染293T细胞,转染后6 h 更换为完全培养基,培养48和72h后,分别收集富含慢病毒颗粒的细胞上清液,病毒上清液通过超离心浓缩病毒。
以下内容由汉恒生物科技(上海)有限公司精心整理总结。
二、实验材料(一)慢病毒载体、包装细胞和菌株该病毒包装系统为三质粒系统,组成为pspax2, pMD2G,pHBLV TM系列质粒.1、载体信息(见附录)2、细胞株 293T,慢病毒的包装细胞,为贴壁依赖型成上皮样细胞,生长培养基为DMEM (含10% FBS).贴壁细胞经培养生长增殖形成单层细胞。
3、菌株大肠杆菌菌株DH5α。
用于扩增慢病毒载体和辅助包装载体质粒。
三、包装细胞293T细胞的培养(一) 293T细胞的冻存随着传代的次数增加,293T细胞会出现生长状态下降、突变等。
为了防止此类现象的出现,我们需要在开始就对细胞进行大量冻存,以保证实验的稳定性和持续性。
在细胞对数生长期进行冻存,增加细胞复苏成活率。
1、去掉上清液,加入PBS洗去残留的培养基;2、加入0。
25%的胰酶,消化1~2min后,镜下观察细胞变圆,细胞间间隙加大时,去除胰酶,加入新鲜培养基吹打混匀,移入离心管中.3、细胞计数,将细胞全部晃下,加入 3mL 37 ℃预热的 10% DMEM,用 10mL 移液管进行吹打,较大力吹打 6~8 次即可,不留死角,之后,将所有细胞吸出,置于15mL 离心管中,取 50ul 混匀后的细胞于 1.5mL eppendorf 管中,加入 450ul 10% DMEM,即为 10 倍稀释,混匀,取 10ul 细胞于计数板中计数。
计数板上共 4 大格,每大格 16 小格。
计数时,4 大格均计数,总数除以 4(得每大格细胞数),再乘以 10(10 倍稀释),即为实际 n万/mL 细胞浓度.4、细胞离心,1000rpm,5min。
慢病毒使用操作手册
慢病毒使用操作手册简介:慢病毒(Lentivirus)是一种常用于生命科学研究中的病毒载体,其具有较强的基因转染能力和稳定的基因表达特性。
本操作手册旨在向研究者提供一个详细的慢病毒使用指南,帮助他们顺利进行慢病毒基因转染实验并获得准确可靠的研究结果。
一、慢病毒基本原理慢病毒属于反转录病毒,其基因组为单链RNA。
慢病毒在寄主细胞内通过逆转录过程将RNA转录为DNA,随后将DNA插入宿主基因组中。
这使得慢病毒成为将外源基因稳定集成到宿主基因组中的理想工具。
二、慢病毒使用前准备1. 实验室条件准备:确保工作台面干净整洁,并准备好所需的培养物、培养器具和试剂。
2. 慢病毒载体制备:根据实验需要,选择合适的慢病毒载体,并通过慢病毒包装系统将目标基因插入载体中。
三、慢病毒转染实验步骤1. 细胞培养:将目标细胞接种在培养皿中,并选择合适的培养基进行细胞培养。
2. 慢病毒感染:将预制的慢病毒悬液加入培养皿中,控制感染浓度和时间,以实现最佳的感染效果。
3. 筛选标记:根据实验需要,在感染后适当的时间点添加筛选标记物,如抗生素或荧光标记剂。
4. 选择和扩增:将受筛选标记影响的细胞单克隆分离,扩增和保存。
5. 验证表达:使用合适的实验方法,如western blot或PCR等,来确认目标基因的表达情况。
6. 结果分析:对实验结果进行统计学分析,并绘制适当的图表。
四、注意事项和常见问题解决方案1. 实验前应认真阅读文献,了解慢病毒的基本原理和实验操作流程。
2. 制备慢病毒载体时,应仔细验证目标基因的序列和正确插入。
3. 慢病毒感染时应注意控制感染浓度和时间,避免细胞毒性和非特异性感染。
4. 筛选标记物的选择应根据实验需要和细胞类型进行合理选择。
5. 实验过程中,注意严格遵守实验室安全和生物安全操作规范。
6. 常见问题解决方案:如遇到感染效率低或细胞毒性问题,可以尝试优化感染条件或调整细胞培养条件。
如果基因表达不稳定,可以尝试选择合适的筛选标记物或优化基因载体。
慢病毒使用手册
-Page 3 of 17-
Lentiviral Vector Particle 使用操作手册
E. 用显微镜观察细胞感染情况时应遵从以下步骤:拧紧培养瓶或盖紧培养板, 用 70%乙醇清理培养瓶外壁后拍照,离开显微镜实验台之前,用 70%乙 醇清理显微镜载物台。
F. 废弃的含过病毒的培养基中加入 84 消毒液(1:20 左右),浸泡一天后丢 弃。接触过病毒的枪头,离心管,培养板等其他物品可用 84 消毒液稀释 液处理,也可以用煮沸处理半小时或常规灭菌(121℃,20 min)。
2. 目的细胞感染预实验
实验材料: 96 孔板一块,20-200 µl 移液枪,1-10 µl 移液枪,10 µl 和 200 µl 枪头,1.5Ep
管,Polybrene、ENi.S.,废液缸,口罩,手套等 说明: MOI:是“multiplicity of infection”的缩写,中文为感染复数或者复感染指数,含
-Page 7 of 17-
Lentiviral Vector Particle 使用操作手册
Medium
TU/ml 1x108 1x107 1x106
表 1.感染预实验中的实验组和感染条件
Complete Medium
Complete Medium + 5 µg/ml Polybrene
Eni.S
上海吉凯基因化学技术有限公司
中国上海张江高科技园区爱迪生路 328 号 2 楼 邮编 201203 电话:(86)21 51320189 传真:(86)21 51370635
Shanghai GeneChem Co.,Ltd
Floor 2, NO.328,Aidisheng Rd . Pudong,Shanghai,201203 P.R.C. TE:(86)21 51320189 FAX:(86)21 51370635
慢病毒用户使用手册
慢病毒用户使用手册1.慢病毒概述慢病毒(Lentivirus)是以人类免疫缺陷型病毒(HIV)为基础发展起来的基因治疗载体,它可以感染分裂细胞和非分裂细胞,可有效地感染包括几乎所有的哺乳动物细胞、干细胞和原代细胞。
此外,慢病毒具有嗜核性,可以将外源基因有效地整合到宿主染色体上,从而可以在体内较长期表达。
慢病毒的多种优点,使它成为基因传递的强大而有效的工具,获得了广泛的应用。
2.慢病毒安全操作规范锐赛生物提供的是第三代的慢病毒载体系统,包括1个慢病毒表达载体和3个包装辅助质粒,大大降低了发生同源重组的概率,降低了产生复制能力病毒的可能性。
同时,本系统的慢病毒颗粒是自身失活型(SIV)病毒,即病毒感染靶细胞后不会再感染其他细胞,也不会利用宿主细胞产生新的病毒颗粒,从而提高了安全性。
尽管如此,该病毒仍然具有潜在的生物学危险,因此建议不要使用编码已知或可能会致癌的基因的假病毒,除非已经完全公认某个基因肯定没有致癌性,否则均不建议采用假病毒进行生物学实验。
此外,建议将本系统生产的慢病毒视为二级生物安全水平的生物,使用时请参照如下基础规范进行实验:1.在进入实验室工作时,穿着实验服或隔离服,戴上手套和口罩。
2.操作病毒时请尽量使用生物安全柜,小心不要产生气雾或液体飞溅。
3.如果使用普通超净工作台操作病毒,请在打开含有病毒的容器盖子前关闭超净台的风机(由于超净台风向外排,有可能将病毒吹向操作者),并尽快操作;尽量缩短开盖后的病毒在关闭了排风机的超净台中停留的时间,封闭所有含有病毒的容器、耗材、废液后,再打开超净台风机。
4.如果操作时台面有病毒污染,请立即用75%酒精加1%的SDS 溶液擦拭。
接触过病毒的枪头,离心管,培养板,培养液请用75%酒精加1%的SDS 溶液或于84 消毒液浸泡过夜后弃去。
5.如需离心,应使用密封性好的离心管,或用封口膜封口后离心。
6.实验结束,脱掉手套前先消毒再摘除手套,随后用肥皂洗手。
Fitgene慢病毒使用说明
Fitgene慢病毒使用说明慢病毒使用说明1. 慢病毒的操作安全性说明1.1 慢病毒的安全性辉骏生物提供的慢病毒载体已经经过了一系列的遗传改造,能够最大限度的保证实验的安全性。
(1)编码HIV-1的毒性基因已经被全部删除,并替换入了外源的目的基因片段,慢病毒感染宿主细胞时,只会介导目的基因的表达,因此包装出的慢病毒为属于假型病毒,无致病性;(2)慢病毒颗粒在感染宿主细胞后并不能进行自我复制,不能再次感染其它类型的细胞,其危险性被大大降低了;(3)慢病毒包装必需的3种蛋白质的基因分别位于3个辅助载体上,并且与慢病毒表达载体相互独立,只有当四质粒共转染包装细胞时才可以包装产生慢病毒,最大限度地降低了慢病毒的重组概率;(4)VSV-G是水泡口炎病毒(Vesicular Stomatitis Virus)的G糖蛋白,它替代了HIV-1原始的包膜蛋白,进一步降低了病毒恢复成野生型的概率;(5)慢病毒感染宿主细胞时会整合入宿主细胞的基因组内,并且这种整合更偏向于基因表达活跃区,另外慢病毒LTR的转录激活能力也相对较低,因此激活沉默区原癌基因的概率和能力也比一般的逆转录病毒低;(6)迄今为止尚未出现慢病毒四质粒包装系统的任何重组报道,也未见感染HIV-1后的致瘤事件。
1.2 慢病毒操作规范尽管对慢病毒载体的一系列改造已经最大限度地保证了其使用的安全,但是慢病毒的使用仍然具有潜在的危险,因此操作时需要严格遵守安全规范。
具体要求如下:(1)所有操作均应在生物安全柜中进行,如果实验室只配备了超净工作台,则不能开启排风系统;(2)慢病毒操作者应穿着实验服,并佩戴一次性手套、口罩,谨防病毒接触眼、耳、口、鼻和伤口等;(3)严格操作,避免产生病毒气雾或喷溅,如操作台等不小心被病毒污染,应立即用1%的SDS溶液擦拭干净;(4)严格注意被病毒污染过的尖锐物品,防止不小心被病毒污染物划伤;(5)最好使用细胞培养瓶培养含病毒的细胞,当用到细胞培养板时,应注意避免病毒洒落;(6)利用显微镜观察细胞感染时,应将含有病毒的细胞培养板或细胞培养皿封紧,并用70%乙醇擦拭外壁;(7)显微镜台、生物安全柜台面等使用后,需用70%乙醇擦拭;(8)实验后,所有接触过病毒的实验用品应立即用巴氏消毒液浸泡:培养基和枪头等浸泡一天后丢弃;可回收的器皿浸泡巴氏消毒液一小时后用自来水冲洗干净,再进行常规灭菌处理;(9)操作人员在完成实验后,应立即清洗双手。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
LentiCRISPRv2 and lentiGuide-Puro: lentiviral CRISPR/Cas9 and single guide RNA CRISPR (C lustered R egularly I nterspaced S hort P alindromic R epeats) is a microbial nuclease system involved in defense against invading phages and plasmids. CRISPR loci in microbial hosts contain a combination of CRISPR-associated (Cas) genes as well as non-coding RNA elements capable of programming the specificity of the CRISPR-mediated nucleic acid cleavage. Lentiviral CRISPR/Cas can infect a broad variety of mammalian cells by co-expressing a mammalian codon-optimized Cas9 nuclease along with a single guide RNA (sgRNA) to facilitate genome editing (Shalem*, Sanjana*, et al., Science 2014). Protocols for cloning into the lentiviral transfer plasmid and general considerations for producing lentivirus are described below. Separate protocols are available for amplifying the genome-scale CRISPR knock-out (GeCKO) libraries. This protocol is for creating individual lentiviral CRISPR plasmids targeting a single genomic locus.lentiCRISPRv2 (one vector system): This plasmid contains two expression cassettes, hSpCas9 and the chimeric guide RNA. The vector can be digested using BsmB I, and a pair of annealed oligos can be cloned into the single guide RNA scaffold. The oligos are designed based on the target site sequence (20bp) and needs to be flanked on the 3' end by a 3bp NGG PAM sequence, as shown on the next page.lentiGuide-Puro (two vector system): This plasmid expressed only the chimeric guide RNA. It does not contain Cas9. Please use lentiCas9-Blast (a separate lentiviral construct that delivers hSpCas9 and blasticidin resistance) to first integrate Cas9 into your cell line. The lentiGuide-Puro vector can be digested using BsmB I, and a pair of annealed oligos can be cloned into the single guide RNA scaffold. The oligos are designed based on the target site sequence (20bp) and needs to be flanked on the 3' end by a 3bp NGG PAM sequence, as shown on the next page.Which vector to use: lentiCRISPRv2 is identical to the original lentiCRISPRv1 but produces nearly 10X higher titer virus. lentiGuide-Puro produces >100X higher titer virus over lentiCRISPRv1 and should be used in cell lines where Cas9 has already been integrated in (e.g. using the separate lentiCas9-Blast lentivirus). For applications where Cas9 cannot first be introduced (e.g. primary cells), lentiCRISPRv2 is recommended. After transduction, use puromycin to select for cells with lentiCRISPRv2 or lentiGuide-Puro.Lentiviral production: Before starting any lentiviral work, please ensure compliance with your Environmental Health and Safety office and government/organization/university. Briefly, to make lentivirus, a transfer plasmid (e.g. lentiCRISPRv2 or lentiGuide-Puro) must be co-transfected into HEK293(F)T cells with the packaging plasmids pVSVg (AddGene 8454) and psPAX2 (AddGene 12260). As a positive control for viral production, we often use a CMV-EGFP lentiviral transfer plasmid (eg. AddGene 19319).Target design notes and online resources: For application of Cas9 for site-specific genome editing in eukaryotic cells and organisms, we have computationally identified suitable target sites for the S. pyogenes Cas9 and calculated most likely off-targets within the genome. Please visit to access these Cas9 target design tools. Complete plasmid sequences, protocols, a discussion forum and additional information can be found at the Zhang Lab GeCKO website: /gecko/ . Citation: Please reference the following publications for the use of this material.Improved lentiviral vectors and genome-wide libraries for CRISPR screening. Sanjana NE*, Shalem O*, Zhang F. Nature Methods (2014).Genome-scale CRISPR-Cas9 knockout screening in human cells. Shalem O*, Sanjana NE*, Hartenian E, Shi X, Scott DA, Mikkelsen T, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (2014). Science, 343, 83-7. DOI: 10.1126/science.1247005Target Guide Sequence Cloning ProtocolIn order to clone the target sequence into the lentiCRISPRv2 or lentiGuide-Puro backbone, synthesize two oligos of the following form. All plasmids have the same overhangs after BsmBI digestion and the same oligos can be used for cloning into lentiCRISPRv2, lentiGuide-Puro or lentiCRISPRv1.Example oligo design : Note that the NGG PAM is not included in the designed oligos. Oligonucleotide ordering tips : Standard de-salted oligos (usually the most inexpensive synthesis) are sufficient forcloning. If not already resuspended, dilute each oligo to 100 µM in sterile water or TE.* * * * *Lentiviral vector digestion, oligo annealing and cloning into digested vector:1. Digest and dephosphorylate 5ug of the lentiviral CRISPR plasmid with BsmB I for 30 min at 37C: 5 ug lentiCRISPRv2 or lentiGuide-Puro 3 ul FastDigest BsmB I (Fermentas) 3 ul FastAP (Fermentas) 6 ul 10X FastDigest Buffer 0.6 ul 100 mM DTT (freshly prepared) X ul ddH 2O 60 ul total2. Gel purify digested plasmid using QIAquick Gel Extraction Kit and elute in EB. If BsmBI digested, a ~2kb filler piece should be present on the gel. Only gel purify the larger band . Leave the 2kb band.3. Phosphorylate and anneal each pair of oligos: 1 ul Oligo 1 (100 µM) 1 ul Oligo 2 (100 µM) 1 ul 10X T4 Ligation Buffer (NEB) 6.5 ul ddH 2O 0.5 ul T4 PNK (NEB M0201S) 10 ul total Please use the T4 Ligation Buffer since the buffer supplied with the T4 PNK enzyme does not include ATP (or supplement to 1mM ATP).Put the phosphorylation/annealing reaction in a thermocycler using the following parameters: 37o C 30 min 95o C 5 min and then ramp down to 25o C at 5o C/min4. Dilute annealed oligos from Step 3 at a 1:200 dilution into sterile water or EB.5. Set up ligation reaction and incubate at room temperature for 10 min:X ul BsmB I digested plasmidfrom Step 2 (50ng)1 ul diluted oligo duplex from Step 4 5 ul 2X Quick Ligase Buffer (NEB) X ul ddH 2O 10 ul subtotal1 ul Quick Ligase (NEB M2200S) 11 ul total Also perform a negative control ligation (vector-only with water in place of oligos) and transformation.6.Transformation into Stbl3 bacteria . Lentiviral transfer plasmids contain Long-Terminal Repeats (LTRs) and must be transformed into recombination-deficient bacteria. We use homemade Stbl3 (propagated from Invitrogen C7373-03) and get excellent plasmid yields. Although other RecA- strains may work, we have found the most consistent transformations and yields using Stbl3.。